WO2005060969A1 - Pyrimidines with tie2 (tek) activity - Google Patents
Pyrimidines with tie2 (tek) activity Download PDFInfo
- Publication number
- WO2005060969A1 WO2005060969A1 PCT/GB2004/005332 GB2004005332W WO2005060969A1 WO 2005060969 A1 WO2005060969 A1 WO 2005060969A1 GB 2004005332 W GB2004005332 W GB 2004005332W WO 2005060969 A1 WO2005060969 A1 WO 2005060969A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- alkoxy
- amino
- saturated
- formula
- Prior art date
Links
- 0 C*c1c(C=CC)c(*)nc(*)n1 Chemical compound C*c1c(C=CC)c(*)nc(*)n1 0.000 description 1
- JPAVYDWYALYWDD-UHFFFAOYSA-N CC(C)(CCCCCC1)CCC1NC(C(Cl)(Cl)Cl)=O Chemical compound CC(C)(CCCCCC1)CCC1NC(C(Cl)(Cl)Cl)=O JPAVYDWYALYWDD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- This invention relates to compounds, or pharmaceutically acceptable salts thereof, which possess anti-angiogenic activity and are accordingly useful in methods of treatment of disease states associated with angiogenesis in the animal or human body.
- the invention also concerns processes for the preparation of the compounds, pharmaceutical compositions containing the compounds as active ingredient, and methods for the use of the compounds in the manufacture of medicaments for use in the production of anti-angiogenic effects in warmblooded animals such as humans.
- the Tie2 receptor tyrosine kinase also known as TEK
- TEK Tie2 receptor tyrosine kinase
- Angiogenesis is a fundamental process defined as the generation of new blood vessels from existing vasc lature. It is a vital yet complex biological process required for the formation and physiological functions of virtually all the organs. Normally it is transient in nature and is controlled by the local balance of angiogenic and angiostatic factors in a multi- step process involving vessel sprouting, branching and tubule formation by endothelial cells (involving processes such as activation of endothelial cells (ECs), vessel destabilisation, synthesis and release of degradative enzymes, EC migration, EC proliferation, EC organisation and differentiation and vessel maturation).
- ECs endothelial cells
- pathological angiogenesis In the adult, physiological angiogenesis is largely confined to wound healing and several components of female reproductive function and embryonic development. In undesirable or pathological angiogenesis, the local balance between angiogenic and angiostatic factors is dysregulated leading to inappropriate and/or structurally abnormal blood vessel formation. Pathological angiogenesis has been associated with disease states including diabetic retinopathy, psoriasis, cancer, rheumatoid arthritis, atheroma, Kaposi's sarcoma and haemangioma (Fan et al, 1995, Trends Pharmacology. Science. 16: 57-66; Folkman, 1995, Nature Medicine 1 : 27-31).
- VEGF vascular endothelial growth factor
- transmembrane tyrosine kinases which are predominantly endothelial cell specific
- VEGF and the angiopoietins cooperate to regulate various aspects of the angiogenic process during both normal and pathological angiogenesis via signalling through their respective receptors.
- Receptor tyrosine kinases RTKs
- These transmembrane molecules characteristically consist of an extracellular ligand-binding domain connected through a segment in the plasma membrane to an intracellular tyrosine kinase domain.
- Binding of ligand to the receptor results in stimulation of the receptor-associated tyrosine kinase activity that leads to phosphorylation of tyrosine residues on both the receptor and other intracellular molecules. These changes in tyrosine phosphorylation initiate a signalling cascade leading to a variety of cellular responses.
- RTK subfamilies defined by amino acid sequence homology, have been identified.
- fms-like tyrosine kinase receptor Fit or Fltl
- the kinase insert domain-containing receptor KDR (also referred to as Flk-1)
- Flt4 kinase insert domain-containing receptor
- Flt4 Flt4
- Two of these related RTKs, Fit and KDR have been shown to bind VEGF with high affinity (De Vries et al, 1992, Science 255: 989-991; Terman et al, 1992, Biochem. Biophys. Res. Comm. 1992, 187: 1579-1586).
- VEGF vascular endothelial growth factor
- the Tie receptors and their ligands, the angiopoietins co-operate closely with VEGF during both normal and pathological angiogenesis.
- the transmembrane receptors Tiel and Tie2 constitute a family of endothelial cell specific tyrosine kinase receptors involved in maintenance of blood vessel integrity and which are involved in angiogenic outgrowth and vessel remodelling.
- Tiel and Tie2 share a number of features (e.g. the intracellular domains of both these receptors each contain a tyrosine kinase domain interrupted by a kinase insert region) and thus constitute a distinct RTK subfamily.
- Overall sequence identity between Tiel and Tie2 receptors at the amino acid level is 44% while their intracellular domains exhibit 76% homology.
- Targeted disruption of the Tiel gene results in a lethal phenotype characterised by extensive haemorrhage and poor microvessel integrity (Puri, M. et al. 1995 EMBO Journal: 14:5884-5891).
- Tie-1 may inhibit apoptosis via the PI 3 kinase/ Akt signal transduction pathway (Kontos, CD., et al., 2002 Molecular and Cellular Biology : 22, 1704-1713).
- angiopoietins a number of ligands, designated the angiopoietins have been identified for Tie2 of which Angiopoietin 1 (Angl) is the best characterised. Binding of Angl induces tyrosine phosphorylation of the Tie2 receptor via autophosphorylation and subsequently activation of its signalling pathways via signal transduction.
- Ang2 has been reported to antagonise these effects in endothelial cells (Maisonpierre, P. et al. 1997 Science: 277, 55-60).
- the knock-out and transgenic manipulation of Tie2 and its ligands suggest that stringent spatial and temporal control of Tie2 signalling is imperative for the correct development of new vasculature.
- Activation of the Tie2 receptor by Angl inhibits apoptosis (Papapetropoulos, A., et al., 2000 Journal of Biological Chemistry : 275 9102-9105), promotes sprouting in vascular endothelial cells (Witzenbicher, B., et al., 1998 Journal of Biological Chemistry: 273, 18514-18521) and in vivo promotes blood vessel maturation during angiogenesis and reduces the permeability and consequent leakage from adult micro vessels (Thurston, G. et al., 2000 Nature Medicine: 6, 460-463).
- Tie2 receptor is reported to be involved in the branching, sprouting and outgrowth of new vessels and recruitment and interaction of periendothelial support cells important in maintaining vessel integrity and overall appears to be consistent with promoting microvessel stability. Absence of Tie2 activation or inhibition of Tie2 auto phosphorylation may lead to a loss of vascular structure and matrix/cell contacts (Thurston, G., Cell Tissue Res (2003), 314: 61-69) and in turn may trigger endothelial cell death, especially in the absence of survival or growth stimuli.
- Tie2 kinase activity may provide an anti-angiogenic effect and thus have application in the therapy of disease states associated with pathological angiogenesis.
- Tie2 expression has been shown to be up-regulated in the neovasculature of a variety of tumours (e.g. Peters, K.G. et al, British Journal of Cancer 1998; 77,51-56) suggesting that inhibiting Tie2 kinase activity will result in anti-angiogenic activity.
- studies with soluble Tie2 receptor extracellular domain
- VEGF A and Angl reported to collaborate to induce angiogenesis and produce non-leaky mature vessels Thurston, G, et al., 1999 Science: 286, 2511-2514). It is quite possible that a mix of such angiogenic processes even exist within a single tumour. Tie2 has also been shown to play a role in the vascular abnormality called venous malformation (VM) (Mulliken, J.B. & Young, A.E. 1998, Vascular birthmarks: W. B. Saunders, Philadelphia). Such defects can either be inherited or can arise sporadically. VM's are commonly found in the skin or mucosal membranes but can affect any organ.
- VM venous malformation
- Upregulation of Tie2 expression has also been found within the vascular synovial pannus of arthritic joints in humans, which is consistent with the role of inappropriate neovascularisation. Such examples provide further indications that inhibition of Tie2 phosphorylation and subsequent signal transduction will be useful in treating disorders and other occurrences of inappropriate neovascularisation. To date only a few inhibitors of Tie2 are known in the art.
- Internation Application No: WO 04/013141 describes a group of condensed pyridines and pyrimi dines and International Application No: WO 04/058776 describes a group of pryidine and pyrimidine compounds.
- WO 04/058776 describes a group of pryidine and pyrimidine compounds.
- R and R are independently selected from hydrogen, (l-6C)alkylsulfonyl, phenyl(CH 2 ) u - wherein u is 0, 1, 2, 3, 4, 5 or 6, (l-6C)alkanoyl, (l-6C)alkyl, (l-6C)alkoxycarbonyl,
- R 3 is selected from hydrogen, (l-6C)aLkyl or (l-6C)alkoxy, wherein the (l-6C)alkyl and the
- (l-6C)alkoxy groups are optionally substituted by one or more groups independently selected from fluoro, hydroxy, (l-6C)alkyl, (l-6C)alkoxy, amino, mono(l-6C)alkylamino, di-[(l-6C)alkyl] amino, carbamoyl, mono(l-6C)alkylcarbamoyl or di-[(l-6C)alkyl]carbamoyl, a saturated or partially saturated 3 to 7 membered heterocyclic ring or a 5 or 6 membered heteroaryl ring, wherein said heterocyclic and heteroaryl rings are optionally independently substituted by one or more of the following: (l-4C)alkyl, (l-4C)alkoxy, hydroxy, amino, mono(l-6C)alkylamino or di-[(l-6C)alkyl]amino or a saturated or partially saturated 3 to 7 membered heterocyclic ring; or R represents a group -NR R as defined
- R 4 is selected from hydrogen, (l-6C)alkyl or (l-6C)alkoxy;
- A represents an aryl group or a 5 or 6 membered heteroaryl ring selected from furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl;
- R 5 is selected from cyclopropyl, cyano, halo, (l-6C)alkoxy or (l-6C)alkyl, wherein the (l-6C)alkyl and the (l-6C)alkoxy groups are optionally substituted by cyano or by one or more fluoro;
- n O, 1, 2 or 3;
- L is attached meta or para on ring A with respect to the point of attachment of the ethynyl group and represents -C(R a R b )C(O)N(R 9 )-, -N(R 8 )C(O)C(R a R b )-, -N(R 8 )C(O)N(R 9 )-, -N(R 8 )C(O)O-, or -OC(O)-N(R 9 )-, wherein R 8 and R 9 independently represent hydrogen or (l-6C)alkyl and wherein R and R b independently represent hydrogen or (l-6C)alkyl or R a and R b together with the carbon atom to which they are attached represent (3-6C)cycloalkyl ;
- B represents a (3-7C)cycloalkyl ring, a saturated or partially saturated 3 to 7 membered heterocyclic ring, an aryl group, a 5 or 6 membered heteroaryl ring selected from furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl, or a 8, 9 or 10 membered bicyclic group which optionally contains 1, 2, 3 or 4 heteroatoms independently selected from N, O and S and which is saturated, partially saturated or aromatic; R 6 is selected from halo, cyano, oxo, a (3-7C)cycloalkyl ring
- R 6 is selected from (l-6C)alkyl or (l-6C)alkoxy, wherein the (l-6C)alkyl, -S(O) p -(l-6C)alkyl and the (l-6C)alkoxy groups are optionally substituted by one or more groups independently selected from cyano, fluoro, hydroxy, (l-6C)alkoxy, amino, mono(l-6C)alkylamino, di-[(l-6C)alkyl]amino, a (3-7C)cycloalkyl ring or a saturated or partially saturated 3 to 7 membered heterocyclic ring; wherein the (3-7C)cycloalkyl ring and saturated or partially saturated 3 to 7 membered heterocyclic ring are optionally independently substituted by one or more groups selected from (l-6C)alkyl; and
- n 0, 1, 2 or 3;
- R 1 and R 2 are independently selected from hydrogen, (l-6C)alkylsulfonyl, phenyl(CH 2 ) u - wherein u is 0, 1, 2, 3, 4, 5 or 6, (l-6C)alkanoyl, (l-6C)alkyl, (l-6C)alkoxycarbonyl, or (3-6C)cycloalkyl(CH 2 ) x - in which x is 0, 1, 2, 3, 4, 5 or 6, or R 1 and R 2 together with the nitrogen atom to which they are attached represent a saturated or partially saturated 3 to 7 membered heterocyclic ring optionally containing another hetero atom selected from N or O; wherein the alkyl and the cycloalkyl groups are optionally substituted by one or more groups selected from fluoro, hydroxy, (l-6C)alkyl, (l-6C)alkoxy, amino, mono(l-6C)alkylamino or di-[(l-6C)alkyl] amino, a saturated or partially saturated 3 to 7
- R 3 is selected from hydrogen, (l-6C)alkyl or (l-6C)alkoxy, wherein the alkyl and the alkoxy groups are optionally substituted by one or more groups selected from fluoro, hydroxy, (l-6C)alkyl, (l-6C)alkoxy, amino, mono(l-6C)alkylamino or di-[(l-6C)alkyl]amino, a saturated or partially saturated 3 to 7 membered heterocyclic ring or a 5 or 6 membered heteroaryl ring, wherein said heterocyclic and heteroaryl rings are optionally independently substituted by one or more of the following: (l-4C)alkyl, hydroxy, amino, mono(l-6C)alkylamino or di-[(l-6C)alkyl] amino or a saturated or partially saturated 3 to 7 membered heterocyclic ring; or R 3 represents a group -NR 1 R 2 as defined above;
- R 4 is selected from hydrogen, (l-6C)alkyl or (l-6C)alkoxy;
- A represents an aryl group or a 5 or 6 membered heteroaryl ring selected from furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl;
- R 5 is selected from cyano, halo, (l-6C)alkoxy or (l-6C)alkyl optionally substituted by cyano or by one or more fluoro;
- n O, 1, 2 or 3;
- L is attached meta or para on ring A with respect to the point of attachment of the ethynyl group and represents -C(R a R b )C(O)N(R 9 )-, -N(R 8 )C(O)C(R a R b )- , -N(R 8 )C(O)N(R 9 )-, -N(R 8 )C(O)O-, or -OC(O)N(R 9 )-, wherein R 8 and R 9 independently represent hydrogen or (l-6C)alkyl and wherein R a and R b independently represent hydrogen or (l-6C)alkyl or R a and R b together with the carbon atom to which they are attached represent (3-6C)cycloalkyl ; B represents a (3-7C)cycloalkyl ring, an aryl group or a 5 or 6 membered heteroaryl ring selected from furyl, pyrroiyl, thienyl,
- R 6 is selected from halo, cyano, a saturated or partially saturated 3 to 7 membered heterocyclic ring or an alkanoylamino group -N(R c )C(O)(l-6C)alkyl in which R c is hydrogen or (l-6C)alkyl; or R 6 is selected from (l-6C)alkyl or (l-6C)alkoxy, wherein the alkyl and the alkoxy groups are optionally substituted by one or more groups selected from cyano, fluoro, hydroxy, (l-6C)alkoxy, amino, mono(l-6C)alkylamino, di-[(l-6C)alkyl]amino, or a saturated or partially saturated 3 to 7 membered heterocyclic ring;
- n O, 1, 2 or 3;
- R 1 and R 2 are independently selected from hydrogen, (l-6C)alkylsulfonyl, phenyl(CH 2 ) u - wherein u is 0, 1, 2, 3, 4, 5 or 6, (l-6C)alkanoyl, (l-6C)alkyl, (l-6C)alkoxycarbonyl,
- R 3 is selected from hydrogen, (l-6C)alkyl or (l-6C)alkoxy, wherein the (l-6C)alkyl and the (l-6C)alkoxy groups are optionally substituted by one or more groups independently selected from fluoro, hydroxy, (l-6C)alkyl, (l-6C)alkoxy, amino, mono(l-6C)alkylamino, di-[(l-6C)alkyl]amino, carbamoyl, mono(l-6C)alkylcarbamoyl or di-[(l-6C)alkyl]carbamoyl, a saturated or partially saturated 3 to 7 membered heterocyclic ring or a 5 or 6 membered heteroaryl ring, wherein said heterocyclic and heteroaryl rings are optionally independently substituted by one or more of the following: (l-4C)alkyl, (l-4C)alkoxy, hydroxy, amino, mono(l-6C)alkylamino or di-[(l-6
- R »4 is selected from hydrogen, (l-6C)alkyl or (l-6C)alkoxy;
- A represents an aryl group or a 5 or 6 membered heteroaryl ring selected from furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl;
- R 5 is selected from cyclopropyl, cyano, halo, (l-6C)alkoxy or (l-6C)alkyl, wherein the (l-6C)alkyl and the (l-6C)alkoxy groups are optionally substituted by cyano or by one or more fluoro;
- n O, 1, 2 or 3;
- L is attached meta or para on ring A with respect to the point of attachment of the ethynyl group and represents -C(R a R )C(O)N(R 9 )-, -N(R 8 )C(O)C(R a R b )-, -N(R 8 )C(O)N(R 9 )-, -N(R 8 )C(O)O-, or -OC(O)-N(R 9 )-, wherein R 8 and R 9 independently represent hydrogen or (l-6C)alkyl and wherein R a and R b independently represent hydrogen or (l-6C)alkyl or R a and R b together with the carbon atom to which they are attached represent (3-6C)cycloalkyl ;
- B represents a (3-7C)cycloalkyl ring, a saturated or partially saturated 3 to 7 membered heterocyclic ring, an aryl group, a 5 or 6 membered heteroaryl ring selected from furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl, or a 8, 9 or 10 membered bicyclic group which optionally contains 1, 2, 3 or 4 heteroatoms independently selected from N, O and S and which is saturated, partially saturated or aromatic;
- R 6 is selected from halo, cyano, a (3-7C)cycloalkyl ring, a saturated or partially saturated 3 to 7 membered heterocyclic ring or an alkanoylamino group -N(R c )C(O)(l-6C)alkyl in which R c is hydrogen or (l-6C)alkyl; or R 6 is selected from (l-6C)alkyl or (l-6C)alkoxy, wherein the (l-6C)alkyl and the
- (l-6C)alkoxy groups are optionally substituted by one or more groups independently selected from cyano, fluoro, hydroxy, (l-6C)alkoxy, amino, mono(l-6C)alkylamino, di-[(l-6C)alkyl]amino, a (3-7C)cycloalkyl ring or a saturated or partially saturated 3 to 7 membered heterocyclic ring;
- n 0, 1, 2 or 3;
- B is a (3-7C)cycloalkyl ring or a saturated or partially saturated 3 to 7 membered heterocyclic ring or a saturated or partially saturated 8, 9 or 10 membered bicyclic group
- the rings and bicyclic group optionally bear 1 or 2 oxo or thioxo substituents; and salts thereof, particularily pharmaceutically acceptable salts thereof.
- R 1 and R 2 are independently selected from hydrogen, (l-6C)alkylsulfor ⁇ yl, phenyl(CH 2 ) u - wherein u is 0, 1, 2, 3, 4, 5 or 6, (l-6C)alkanoyl, (l-6C)alkyl, (l-6C)alkx>xycarbonyl,
- R 3 is selected from hydrogen, (l-6C)alkyl or (l-6C)alkoxy, wherein the (l-6C)alkyl and the (l-6C)alkoxy groups are optionally substituted by one or more groups independently selected from fluoro, hydroxy, (l-6C)alkyl, (l-6C)alkoxy, amino, mono(l-6C)alkylamino, di-[(l-6C)alkyl]amino, carbamoyl, mono(l-6C)alkylcarbamoyl or di-[(l-6C)alkyl]carbamoyl, a saturated or partially saturated 3 to 7 membered heterocyclic ring or a 5 or 6 membered heteroaryl ring, wherein said heterocyclic and heteroaryl rings are optionally independently substituted by one or more of the following: (l-4C)alkyl, (l-4C)alkoxy, hydroxy, amino, mono(l-6C)alkylamino or di-[(l-6
- R 4 is selected from hydrogen, (l-6C)alkyl or (l-6C)alkoxy;
- A represents an aryl group or a 5 or 6 membered heteroaryl ring selected from furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl;
- R 5 is selected from cyclopropyl, cyano, halo, (l-6C)alkoxy or (l-6C)alkyl, wherein the (l-6C)alkyl and the (l-6C)alkoxy groups are optionally substituted by cyano or by one or more fluoro; n is O, 1, 2 or 3;
- L is attached meta or para on ring A with respect to the point of attachment of the ethynyl group and represents -C(R a R b )C(O)N(R 9 )-, -N(R 8 )C(O)C(R a R b )-, -N(R 8 )C(O)N(R 9 , -N(R 8 )C(O)O-, or-OC(O)N(R 9 )-, wherein R 8 and R 9 independently represent hydrogen or (l-6C)alkyl and wherein R a and R b independently represent hydrogen or (l-6C)alkyl or R a and R b together with the carbon atom to which they are attached represent (3-6C)cycloalkyl ;
- B represents a (3-7C)cycloalkyl ring, a saturated or partially saturated 3 to 7 membered heterocyclic ring, an aryl group, a 5 or 6 membered heteroaryl ring selected from furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl, or a 8, 9 or 10 membered bicyclic group which optionally contains 1 , 2, 3 or 4 heteroatoms independently selected from N, O and S and which is saturated, partially saturated or aromatic;
- R 6 is selected from one of the two following groups:
- R 6 is selected from halo, cyano, a (3-7C)cycloalkyl ring, a saturated or partially saturated 3 to 7 membered heterocyclic ring or an alkanoylamino group -N(R c )C(O)(l-6C)alkyl in which R c is hydrogen or (l-6C)alkyl; or R is selected from (l-6C)alkyl or (l-6C)alkoxy, wherein the (l-6C)alkyl and the (l-6C)alkoxy groups are optionally substituted by one or more groups independently selected from cyano, fluoro, hydroxy, (l-6C)alkoxy, amino, mono(l-6C)alkyl amino, di-[(l-6C)alkyl]amino, a (3-7C)cycloalkyl ring or a saturated or partially saturated 3 to 7 membered heterocyclic ring; or (ii) R is selected from halo, cyano, oxo
- n 0, 1, 2 or 3;
- B is a (3-7C)cycloalkyl ring or a saturated or partially saturated 3 to 7 membered heterocyclic ring or a saturated or partially saturated 8, 9 or 10 membered bicyclic group
- the rings and bicyclic group optionally bear 1 or 2 oxo or thioxo substituents; and salts thereof, particularily pharmaceutically acceptable salts thereof.
- R and R are independently selected from hydrogen, (l-6C)alkylsulfonyl, phenyl(CH 2 ) u - wherein u is 0, 1, 2, 3, 4, 5 or 6, (l-6C)alkanoyl, (l-6C)alkyl, (l-6C)alkoxycarbonyl, (3-6C)cycloalkyl(CH 2 ) x - in which x is 0, 1, 2, 3, 4, 5 or 6 , or a 5 or 6 membered heteroaryl ring, or R and R together with the nitrogen atom to which they are attached represent a saturated or partially saturated 3 to 7 membered heterocyclic ring optionally containing another heteroatom selected from N or O; wherein the (l-6C)alkyl, the (l-6C)alkanoyl and the (3-6C)cycloalkyl groups are optionally substituted by one or more groups independently selected from fluoro, hydroxy, (l-6C)alkyl, (l-6C)alkoxy, (l-6C)
- R 4 is selected from hydrogen, (l-6C)alkyl or (l-6C)alkoxy;
- A represents an aryl group or a 5 or 6 membered heteroaryl ring selected from furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl;
- R 5 is selected from cyclopropyl, cyano, halo, (l-6C)alkoxy or (l-6C)alkyl, wherein the (l-6C)alkyl and the (l-6C)alkoxy groups are optionally substituted by cyano or by one or more fluoro;
- n 0, 1, 2 or 3;
- L is attached meta or para on ring A with respect to the point of attachment of the ethynyl group and represents -C(R a R b )C(O)N(R 9 )-, -N(R 8 )C(O)C(R a R b )-, -N(R 8 )C(O)N(R 9 )-, -N(R 8 )C(O)O-, or -OC(O)-N(R 9 )-, wherein R 8 and R 9 independently represent hydrogen or (l-6C)alkyl and wherein R a and R b independently represent hydrogen or (l-6C)alkyl or R a and R b together with the carbon atom to which they are attached represent (3-6C)cycloalkyl;
- B represents a (3-7C)cycloalkyl ring, a saturated or partially saturated 3 to 7 membered heterocyclic ring, an aryl group, a 5 or 6 membered heteroaryl ring selected from furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl, or a 8, 9 or 10 membered bicyclic group which optionally contains 1, 2, 3 or 4 heteroatoms independently selected from N, O and S and which is saturated, partially saturated or aromatic;
- R > 6 is selected from one of the two following groups:
- R is selected from halo, cyano, a (3-7C)cycloalkyl ring, a saturated or partially saturated 3 to 7 membered heterocyclic ring or an alkanoylamino group -N(R c )C(O)(l-6C)alkyl in which R c is hydrogen or (l-6C)alkyl; or R 6 is selected from (l-6C)alkyl or (l-6C)alkoxy, wherein the (l-6C)alkyl and the (l-6C)alkoxy groups are optionally substituted by one or more groups independently selected from cyano, fluoro, hydroxy, (l-6C)alkoxy, amino, mono(l-6C)alkylamino, di-[(l-6C)alkyl]amino, a (3-7C)cycloalkyl ring or a saturated or partially saturated 3 to 7 membered heterocyclic ring; or
- R is selected from halo, cyano, oxo, a (3-7C)cycloalkyl ring, a saturated or partially saturated 3 to 7 membered heterocyclic ring or an alkanoylamino group -N(R c )C(O)(l-6C)alkyl in which R c is hydrogen or (l-6C)alkyl; or R 6 is selected from (l-6C)alkyl, -S(O) p -(l-6C)alkyl wherein p is 0, 1 or 2, or (l-6C)alkoxy, wherein the (l-6C)alkyl, -S(O) p -(l-6C)alkyl and the (l-6C)alkoxy groups are optionally substituted by one or more groups independently selected from: cyano, fluoro, hydroxy, (l-6C)alkoxy, amino, mono(l-6C)alkylamino, di(l-6C)alkylamino, a
- n 0, 1, 2 or 3;
- B is a (3-7C)cycloalkyl ring or a saturated or partially saturated 3 to 7 membered heterocyclic ring or a saturated or partially saturated 8, 9 or 10 membered bicyclic group
- the rings and bicyclic group optionally bear 1 or 2 oxo or thioxo substituents;
- R 10 and R 11 are independently selected from hydrogen or (l-6C)alkyl; and salts thereof, particularily pharmaceutically acceptable salts thereof.
- R 1 and R 2 are independently selected from hydrogen, (l-6C)alkylsulfonyl, phenyl(CH 2 ) u - wherein u is 0, 1, 2, 3, 4, 5 or 6, (l-6C)alkanoyl, (l-6C)alkyl, (l-6C)alkoxycarbonyl, or (3-6C)cycloalkyl(CH 2 ) x - in which x is 0, 1, 2, 3, 4, 5 or 6, or R 1 and R 2 together with the nitrogen atom to which they are attached represent a saturated or partially saturated 3 to 7 membered heterocyclic ring optionally containing another heteroatom selected from N or O; wherein the alkyl and the cycloalkyl groups are optionally substituted by one or more groups selected from fluoro, hydroxy, (l-6C)alkyl, (l-6C)alkoxy, amino, mono(l-6C)alkylamino or di-[(l-6C)alkyl]amino, a saturated or partially saturated 3 to
- R 4 is selected from hydrogen, (l-6C)alkyl or (l-6C)alkoxy;
- A represents an aryl group or a 5 or 6 membered heteroaryl ring selected from furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl;
- R 5 is selected from cyano, halo, (l-6C)alkoxy or (l-6C)alkyl optionally substituted by cyano or by one or more fluoro;
- n O, 1, 2 or 3;
- L is attached meta or para on ring A with respect to the point of attachment of the ethynyl group and represents -C(R a R b )C(O)N(R 9 )-, -N(R 8 )C(O)C(R a R b )-, -N(R 8 )C(O)N(R 9 )-, -N(R 8 )C(O)O-, or -OC(O)N(R 9 )-, wherein R 8 and R 9 independently represent hydrogen or (l-6C)alkyl and wherein R a and R b independently represent hydrogen or (l-6C)alkyl or R a and R b together with the carbon atom to which they are attached represent (3-6C)cycloalkyl;
- B represents a (3-7C)cycloalkyl ring, an aryl group or a 5 or 6 membered heteroaryl ring selected from furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl;
- R 6 is selected from halo, cyano, a saturated or partially saturated 3 to 7 membered heterocyclic ring or an alkanoylamino group -N(R c )C(O)(l-6C)alkyl in which R c is hydrogen or (l-6C)alkyl; or R 6 is selected from (l-6C)alkyl or (l-6C)alkoxy, wherein the alkyl and the alkoxy groups are optionally substituted by one or more groups selected from cyano, fluoro, hydroxy, (l-6C)alkoxy, amino, mono(l-6C)alkylamino, di-[(l-6C)alkyl]amino, or a saturated or partially saturated 3 to 7 membered heterocyclic ring; and
- n 0, 1, 2 or 3;
- R 10 and R 11 are independently selected from hydrogen or (l-6C)alkyl; and salts thereof, particularily pharmaceutically acceptable salts thereof.
- R 1 and R 2 are independently selected from hydrogen or (l-6C)alkyl
- R 4 is selected from hydrogen, (l-6C)alkyl or (l-6C)alkoxy;
- A represents an aryl group or a 5 or 6 membered heteroaryl ring selected from furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5- triazinyl;
- R 5 is selected from halo, (l-6C)alkyl or (l-6C)alkoxy;
- n O, 1, 2 or 3;
- L is attached meta or para on ring A with respect to the point of attachment of the ethynyl group and represents -CH 2 C(O)N(R 8 )-, -N(R 9 )C(O)CH 2 -, -N(R 8 )C(O)N(R 9 )-, -N(R 8 )C(O)O-, or -OC(O) N(R 9 )- wherein R 8 and R 9 independently represent hydrogen or (l-6C)alkyl;
- B represents a (3-7C)cycloalkyl ring, an aryl group or a 5 or 6 membered heteroaryl ring selected from furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl;
- R 6 is selected from halo, cyano, a saturated or partially saturated 3 to 7 membered heterocyclic ring or an alkanoylamino group -N(R c )C(O)(l-6C)alkyl in which R c is hydrogen or (l-6C)alkyl; or R 6 is selected from (l-6C)alkyl or (l-6C)alkoxy, wherein the alkyl and the alkoxy groups are optionally substituted by one or more groups selected from cyano, fluoro, hydroxy, (l-6C)alkoxy, amino, mono(l-6C)alkylamino, di-[(l-6C)alkyl] amino, or a saturated or partially saturated 3 to 7 membered heterocyclic ring; and
- n 0, 1, 2 or 3;
- R 10 and R 11 are independently selected from hydrogen or (l-6C)alkyl; and salts thereof, particularily pharmaceutically acceptable salts thereof.
- R and R are independently selected from hydrogen, (l-6C)alkyl or a 5 or 6 membered heteroaryl ring; wherein the (l-6C)alkyl group is optionally substituted by one or more groups independently selected from fluoro, hydroxy, (l-6C)alkyl, (l-6C)alkoxy, (1 -6C)alkoxy( 1 -6C)alkoxy, ( 1 -6C)alkoxy( 1 -6C)alkoxy( 1 -6C)alkoxy, amino, mono(l-6C)alkylamino, di-[(l-6C)alkyl]amino, carbamoyl, mono(l-6C)alkylcarbamoyl, di-[(l-6C)alkyl]carbamoyl or an alkanoylamino group -N(R d )C(O)(l-6C)alkyl in which R d is hydrogen or (l
- R 4 is selected from hydrogen, (l-6C)alkyl or (l-6C)alkoxy;
- A represents an aryl group or a 5 or 6 membered heteroaryl ring selected from furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl;
- R 5 is selected from cyclopropyl, halo, (l-6C)alkyl or (l-6C)alkoxy;
- n 0, 1, 2 or 3;
- L is attached meta or para on ring A with respect to the point of attachment of the ethynyl group and represents -CH 2 C(O)N(R 8 ), -N(R 9 )C(O)CH 2 -, -N(R 8 )C(O)N(R 9 )-, -N(R 8 )C(O) O-, or -OC(O) N(R 9 )-, wherein R 8 and R 9 independently represent hydrogen or (l-6C)alkyl;
- B represents a (3-7C)cycloalkyl ring, an aryl group, a 5 or 6 membered heteroaryl ring selected from furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl, or a 8, 9 or 10 membered bicyclic group which optionally contains 1, 2, 3 or 4 heteroatoms independently selected from N, O and S and which is saturated, partially saturated or aromatic;
- R 6 is selected from halo, cyano, a (3-7C)cycloalkyl ring, a saturated or partially saturated 3 to
- R 6 is selected from (l-6C)alkyl or (l-6C)alkoxy, wherein the (l-6C)alkyl and the (l-6C)alkoxy groups are optionally substituted by one or more groups independently selected from cyano, fluoro, hydroxy, (l-6C)alkoxy, amino, mono(l-6C)alkylamino, di-[(l-6C)alkyl]amino, a (3-7C)cycloalkyl ring or a saturated or partially saturated 3 to 7 membered heterocyclic ring; and
- n 0, 1, 2 or 3;
- B is a (3-7C)cycloalkyl ring, a saturated or partially saturated 3 to 7 membered heterocyclic ring or a saturated or partially saturated 8, 9 or 10 membered bicyclic group, the rings and the bicyclic group optionally bear 1 or 2 oxo or thioxo substituents;
- R 10 and R 11 are independently selected from hydrogen or (l-6C)alkyl; and salts thereof, particularily pharmaceutically acceptable salts thereof.
- alkyl includes both straight-chain and branched-chain alkyl groups such as propyl, isopropyl and tert-butyl.
- references to individual alkyl groups such as "propyl” are specific for the straight-chain version only
- references to individual branched-chain alkyl groups such as “isopropyl” are specific for the branched-chain version only.
- (l-6C)alkoxy includes methoxy, ethoxy and isopropoxy
- (l-6C)alkylamino includes methylamino
- di-[(l-6Calkyl]amino includes dimethylamino, diethylamino and N-methyl-N-isoproylamino
- aryl refers to phenyl or naphthyl, particularily phenyl.
- the invention includes in its definition any such optically active or racemic form which possesses the above-mentioned activity.
- the synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art, for example by synthesis from optically active starting materials or by resolution of a racemic form.
- the above-mentioned activity may be evaluated using the standard laboratory techniques referred to hereinafter. Suitable values for the generic radicals referred to above include those set out below.
- Suitable 5 or 6 membered heteroaryl rings include, for example furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, 1,3,5-triazinyl or pyrazinyl.
- Particular 5 or 6 membered heteroaryl rings include imidazolyl, pyridyl, thiazolyl, thiadiazolyl, pyrimidinyl, isoxazolyl, pyrazolyl and isothiazolyl.
- Suitable saturated or partially saturated 3 to 7 membered heterocyclic rings include, for example oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl,
- a suitable value for such a group which bears 1 or 2 oxo or thioxo substituents is, for example, 2-oxopyrrolidinyl, 2-thioxopyrrolidinyl, 2-oxoimidazolidinyl, 2-thioxoimidazolidinyl, 2-oxopiperidinyl, 2,5-dioxopyrrolidinyl, 2,5-dioxoimidazolidinyl or 2,6-dioxopiperidinyl.
- the saturated or partially saturated 3 to 7 membered heterocyclic rings are optionally substituted by one or more (l-6C)alkyl groups and/or by one or more hydroxy.
- Suitable 8, 9 or 10 membered bicyclic groups include thieno[2,3-b]furanyl, imidazolo[2,l-b]thiazolyl, dihydrocyclopentathiazolyl, tetrahydrocyclopenta[c]pyrazolyl, furo[3,2-b]furanyl, pyrrolopyrrole, thienopyrazolyl, thieno[2,3-b]thiophenyl, indolizinyl, indolyl, isoindolyl, 3H-indolyl, indolin-yl, benzo[b]furanyl, benzo[b]thiophenyl, IH-indazolyl, benzimidazolyl, benzthiazolyl, purinyl, 4H-quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalin
- Particular 8, 9 or 10 membered bicyclic groups include thieno[2,3-b]furanyl, indolizinyl, indolyl, isoindolyl, 3H-indolyl, indolin-yl, benzo[b]furanyl, benzo[b]thiophenyl, IH-indazolyl, benzimidazolyl, benzthiazolyl, purinyl, 4H-quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, chromanyl, isochromanyl, indenyl, naphthalenyl, 2,3-dihydro-l,4-benzodioxinyl and l,3-benzodioxol-5-yl.
- the bicyclic group is optionally substituted by one or more groups R 6 as hereinbefore defined.
- the group A may particularly be attached to the ethynyl group via a carbon atom in the aryl group or in the 5 or 6 membered heteroaryl ring.
- the group B may particularly be attached to the group L via a carbon atom.
- Suitable values for any of the substituents herein, for example the 'R' groups (R 1 to R 11 ) or for various groups within a A, B or L group include: for halo fluoro, chloro, bromo and iodo; for (l-6C)alkyl: methyl, ethyl, propyl, isopropyl and tert-butyl; for (l-6C)alkoxy: methoxy, ethoxy, propoxy, isopropoxy and butoxy; for (l-6C)alkylsulfonyl: methylsulfonyl and ethylsulfonyl; for (l-6C)alkylamino: methylamino, ethylamino, propylamino, isopropylamino and butylamino; for di-[(l-6C)alkyl]amino: dimethylamino, diethylamino, N-ethyl-N-
- (l-4C)alkyl group refers to alkyl groups containing up to 4 carbon atoms.
- (l-4C)alkyl that contain up to 4 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl and tert-butyl.
- reference to a (l-3C)alkyl group refers to alkyl groups containing up to 3 carbon atoms such as methyl, ethyl, propyl and isopropyl.
- the invention relates to all tautomeric forms of the compounds of the formula I forms which exhibit an inhibitory effect on a Tie2 receptor tyrosine kinase.
- pharmaceutically-acceptable salts of compounds of the invention are preferred, other non-pharmaceutically-acceptable salts of compounds of the invention may also be useful, for example in the preparation of pharmaceutically-acceptable salts of compounds of the invention.
- a suitable pharmaceutically acceptable salt of a compound of the formula I is, for example, an acid-addition salt of a compound of the formula I, for example an acid-addition salt with an inorganic or organic acid such as hydrochloric, hydrobromic, sulfuric, trifluoroacetic, citric or maleic acid; or, for example, a salt of a compound of the formula I which is sufficiently acidic, for example an alkali or alkaline earth metal salt such as a calcium or magnesium salt, or an ammonium salt, or a salt with an organic base such as methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
- an acid-addition salt of a compound of the formula I for example an acid-addition salt with an inorganic or organic acid such as hydrochloric, hydrobromic, sulfuric, trifluoroacetic, citric or maleic acid
- a salt of a compound of the formula I which is sufficiently acidic
- pro-drugs of compounds of the invention as herein before or herein after defined.
- Compounds of the invention may be administered in the form of a pro-drug which is broken down in the human or animal body to give a compound of the Formula (I).
- pro-drugs include in-vivo hydrolysable esters of a compound of the Formula (I).
- Various forms of pro-drugs are known in the art. For examples of such pro-drug derivatives, see: a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, et al.
- An in- vivo hydrolysable ester of a compound of the Formula (I) containing a hydroxy group is, for example, a pharmaceutically-acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol.
- Suitable pharmaceutically- acceptable esters for carboxy include C 1-6 alkoxymethyl esters for example methoxymethyl, C 1-6 alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C 3-8 cycloalkoxycarbonyloxyC 1-6 alkyl esters for example 1-cyclohexylcarbonyloxyethyl; l,3-dioxolen-2-onylmethyl esters, for example 5-methyl-l,3-dioxolen-2-onylmethyl; and C i -6 alkoxyc arbonyloxyethyl esters .
- An in- vivo hydrolysable ester of a compound of the Formula (I) containing a hydroxy group includes inorganic esters such as phosphate esters (including phosphoramidic cyclic esters) and -acyloxyalkyl ethers and related compounds which as a result of the in- vivo hydrolysis of the ester breakdown to give the parent hydroxy group/s.
- inorganic esters such as phosphate esters (including phosphoramidic cyclic esters) and -acyloxyalkyl ethers and related compounds which as a result of the in- vivo hydrolysis of the ester breakdown to give the parent hydroxy group/s.
- -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy.
- a selection of in-vivo hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and N-(dialkylaminoethyl)-N-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl.
- Particular novel compounds of the invention include, for example, compounds of the formula I, or salts, particularily pharmaceutically acceptable salts thereof, wherein, unless otherwise stated, each of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , A, B, L, m and n has any of the meanings defined hereinbefore or in paragraphs (a) to (dddd) hereinafter:- (a) when n is 2 or 3, R 5 may be the same or different; (a') when m is 2 or 3, R 6 may be the same or different;
- L is -CH 2 C(O)N(R 9 )-, wherein R 9 is hydrogen or (l-6C)alkyl (particularly R 9 is hydrogen ) ;
- L is -N(R 8 )C(O)CH 2 -, wherein R 8 is hydrogen or (l-6C)alkyl (particularly R 8 is hydrogen);
- L is -N(R 8 )C(O)N(R 9 )-, wherein R 8 and R 9 are independently selected from hydrogen or (l-6C)alkyl (particularly R 8 and R 9 are both hydrogen or in another embodiment one of R 8 and R 9 is hydrogen and the other is methyl)); (d) L is -N(R 8 )C(O) O-, wherein R 8 is hydrogen or (l-6C)alkyl (particularly R 8 is hydrogen or in another embodiment R 8 is methyl);
- L is -OC(O)-N(R 9 ), wherein R 9 is hydrogen or (l-6C)alkyl (particularly R 9 is hydrogen or in another embodiment R 9 is methyl); (e') L is selected from -N(R 8 )C(O)N(R 9 )-, -N(R 8 )C(O)O- or -N(R 8 )C(O-CH 2 - wherein R 8 and R 9 independently represent hydrogen or (l-6C)alkyl.
- Ring B-R 6 where m is 1 or 2, is selected from 5-tert-butyl-l,3,4-thiadiazol-2-yl, 3-methylisoxazol-5-yl, 3-methoxyphenyl, 4-(trifluoromethyl)pyridin-2-yl, 2-(trifluoromethyl)phenyl, 3-(trifluoromethyl)phenyl, 4-(trifluoromethyl)phenyl, 2-fluoro-4-(trifluoromethyl)phenyl, 5-tert-butylisoxazol-3-yl, phenyl and 3-acetylaminophenyl;
- R 1 and R 2 are independently selected from hydrogen, phenyl(CH 2 ) u - wherein u is 0, 1, 2, 3, 4, 5 or 6, (l-6C)alkanoyl, (l-6C)alkyl, (l-6C)alkoxycarbonyl, (3-6C)cycloalkyl(CH 2 ) x - in which x is 0, 1, 2, 3, 4, 5 or 6, or a 5 or 6 membered heteroaryl ring; wherein the (l-6C)alkyl, the (l-6C)alkanoyl and the (3-6C)cycloalkyl groups are optionally substituted by one or more groups (for example 1 or 2), which may be the same or different, selected from fluoro, hydroxy, (l-6C)alkyl, (l-6C)alkoxy, (l-6C)alkoxy(l-6C)alkoxy, (l-6C)alkoxy(l-6C)alkoxy(l-6C)alkoxy, amino, mono(l-6C)
- R 1 and R 2 are independently selected from hydrogen, (l-6C)alkanoyl, (l-6C)alkyl,
- R 1 and R 2 are independently selected from hydrogen, (l-6C)alkanoyl, (l-6C)alkyl or a 5 or 6 membered heteroaryl ring; wherein the (l-6C)alkyl and the (l-6C)alkanoyl groups are optionally substituted by one or more groups (for example 1 or 2), which may be the same or different, as hereinbefore defined in (g); and wherein any heterocyclic and heteroaryl rings within R 1 and or R 2 are optionally independently substituted by one or more groups (for example 1 or 2), which may be the same or different, as hereinbefore defined in (g); (j) R 1 is hydrogen and R 2 is selected from hydrogen, (l-6C)alkylsulfonyl, phenyl(CH 2 ) u - wherein u is 0, 1, 2, 3, 4, 5 or 6, (l-6C)alkanoyl, (l-6C)alkyl, (l-6C)alkoxycarbonyl, (3-6C)cycloal
- any heterocyclic and heteroaryl rings within R 2 are optionally independently substituted by one or more groups (for example 1 or 2), which may be the same or different, as hereinbefore defined in (g);
- R 1 hydrogen and R 2 is selected from hydrogen, (l-6C)alkanoyl, (l-6C)alkyl, (l-6C)alkoxycarbonyl or (3-6C)cycloalkyl(CH 2 ) x - in which x is 0, 1, 2, 3, 4, 5 or 6, or a 5 or 6 membered heteroaryl ring; wherein the (l-6C)alkyl, the (l-6C)alkanoyl and the (3-6C)cycloalkyl groups are optionally substituted by one or more groups (for example 1 or 2), which may be the same or different, as hereinbefore defined in (g); and wherein any heterocyclic and heteroaryl rings within R 2 are optionally independently substituted by one or more groups (for example 1 or 2), which may be the same or different, as hereinbefore defined in (g); (1) R 1 is hydrogen and R 2 is selected from hydrogen, (l-6C)alkanoyl, (l-6C)alkyl or a 5 or 6 membered heteroaryl
- R 1 and R 2 are independently selected from hydrogen, (l-6C)alkylsulfonyl, phenyl(CH 2 ) u - wherein u is 0, 1, 2, 3, 4, 5 or 6, (l-6C)alkanoyl, (l-6C)alkyl, (l-6C)alkoxycarbonyl, (3-6C)cycloalkyl(CH 2 ) x - in which x is 0, 1, 2, 3, 4, 5 or 6, or a 5 or 6 membered heteroaryl ring; wherein the (l-6C)alkyl, the (l-6C)alkanoyl and the (3-6C)cycloalkyl groups are optionally substituted by one or more groups (for example 1 or 2), which may be the same or different, selected from hydroxy, (l-6C)alkoxy, (l-6C)alkoxy(l-6C)alkoxy, amino, mono(l-6C)alkylamino, di-[(l-6C)alkyl]amino, carb
- R 1 and R 2 are independently selected from hydrogen, (l-6C)alkanoyl, (l-6C)alkyl, or a 5 or 6 membered heteroaryl ring; wherein the (l-6C)alkyl and the (l-6C)alkanoyl groups are optionally substituted by one or more groups (for example 1 or 2), which may be the same or different, as hereinbefore defined in (m); and wherein any heterocyclic and heteroaryl rings within R 1 and/or R 2 are optionally independently substituted by one or more groups (for example 1 or 2), which may be the same or different, as hereinbefore defined in (m);
- R 1 is hydrogen and R 2 is selected from hydrogen, (l-6C)alkylsulfonyl, phenyl(CH 2 ) u - wherein u is 0, 1, 2, 3, 4, 5 or 6, (l-6C)alkanoyl, (l-6C)alkyl, (l-6C)alkoxycarbonyl, (3-6C)cycloalkyl(CH 2 ) x - in which x is 0, 1, 2, 3, 4, 5 or 6, or a 5 or 6 membered heteroaryl ring; wherein the (l-6C)alkyl, the (l-6C)alkanoyl and the (3-6C)cycloalkyl groups are optionally substituted by one or more groups (for example 1 or 2), which may be the same or different, as hereinbefore defined in (m); wherein the phenyl is optionally substituted by one or more groups (for example 1 or 2), which may be the same or different, as hereinbefore defined in (m); and wherein any heterocyclic and heteroaryl
- R 1 is hydrogen and R 2 is selected from hydrogen, (l-6C)alkanoyl, (l-6C)alkyl, (l-6C)alkoxycarbonyl, (3-6C)cycloalkyl(CH 2 ) x - in which x is 0, 1, 2, 3, 4, 5 or 6, or a 5 or 6 membered heteroaryl ring; wherein the (l-6C)alkyl, the (l-6C)alkanoyl and the (3-6C)cycloalkyl groups are optionally substituted by one or more groups (for example 1 or 2), which may be the same or different, as hereinbefore defined in (m); and wherein any heterocyclic and heteroaryl rings within R 2 are optionally independently substituted by one or more groups (for example 1 or 2), which may be the same or different, as hereinbefore defined in (m);
- R 1 is hydrogen and R 2 is selected from hydrogen, (l-6C)alkanoyl, (l-6C)alkyl or a 5 or 6 membered heteroaryl ring; wherein the (l-6C)alkyl and the (l-6C)alkanoyl groups are optionally substituted by one or more groups (for example 1 or 2), which may be the same or different, as hereinbefore defined in (m); and wherein any heterocyclic and heteroaryl rings within R 2 are optionally independently substituted by one or more groups (for example 1 or 2), which may be the same or different, as hereinbefore defined in (m);
- R 1 is hydrogen and R 2 is selected from hydrogen, (l-6C)alkanoyl and (l-6C)alkyl; wherein the (l-6C)alkyl and the (l-6C)alkanoyl groups are optionally substituted by one or more groups (for example 1 or 2), which may be the same or different, as hereinbefore defined in (m); and wherein any heterocyclic and heteroaryl rings within R 2 are optionally independently substituted by one or more groups (for example 1 or 2), which may be the same or different, as hereinbefore defined in (m);
- R 1 is hydrogen and R 2 is selected from hydrogen, (l-6C)alkanoyl and (l-6C)alkyl, wherein the (l-6C)alkyl and the (l-6C)alkanoyl groups are optionally substituted by one or more groups (for example 1 or 2), which may be the same or different, selected from hydroxy, (l-4C)alkoxy, (l-4C)alkoxy(l-4C)alkoxy, amino, mono(l-3C)alkylamino, di(l-3C)alkylamino, carbamoyl or-N(R d )C(O)(l-3C)alkyl in which R d is hydrogen or (l-3C)alkyl, or a saturated 5 or 6 membered heterocyclic ring, or a 5 or 6 membered heteroaryl ring, wherein the (l-4C)alkoxy and (l-4C)alkoxy(l-4C)alkoxy and the (l-3C)alkyl groups of
- R 1 is hydrogen and R 2 is selected from hydrogen and (l-6C)alkyl (particularly
- (l-3C)alkyl wherein the (l-6C)alkyl (particularly (l-3C)alkyl) group is optionally substituted by one or more groups (for example 1 or 2), which may be the same or different, as hereinbefore defined in (t); and wherein any heterocyclic and heteroaryl rings within R 2 are optionally independently substituted by one or more groups (for example 1 or 2), which may be the same or different, as hereinbefore defined in (t);
- R 1 is hydrogen and R 2 is (l-6C)alkyl (particularly (l-3C)alkyl), wherein the (l-6C)alkyl (particularly (l-3C)alkyl) group is optionally substituted by one or more groups (for example 1 or 2), which may be the same or different, as hereinbefore defined in (t); and wherein any heterocyclic and heteroaryl rings within R 2 are optionally independently substituted by one or more groups (for example 1 or 2), which may be the same or different, as hereinbefore defined in (t);
- R 1 and R 2 are both hydrogen or R 1 is hydrogen or (l-6C)alkyl and R 2 is (l-6C)alkyl wherein (l-6Calkyl) is optionally substituted by hydroxy, amino, mono(l-6C)alkylamino or di(l-6C)alkylamino, carbamoyl, (l-6C)alkoxy,
- R 1 and R 2 are both hydrogen or R 1 is hydrogen or (l-6C)alkyl and R 2 is (l-6C)alkyl wherein (l-6Calkyl) is optionally substituted by hydroxy, amino, mono(l-6C)alkylamino or di(l-6C)alkylamino, aryl (particularily phenyl) or a saturated or partially saturated 3 to 7 membered heterocyclic ring or a 5 or 6 membered heteroaryl ring; wherein the an aryl ring, saturated or partially saturated 3 to 7 membered heterocyclic ring or a 5 or 6 membered heteroaryl ring is optionally substituted by one or two groups independently selected from (l-4C)alkyl and (l-4C)alkoxy.
- R 1 and R 2 are both hydrogen or R 1 is hydrogen or (l- ⁇ C)alkyl and R 2 is (l-6C)alkyl wherein (l-6Calkyl) is optionally substituted by hydroxy, amino, mono(l-6C)alkylamino or di(l-6C)alkylamino, carbamoyl, (l-6C)alkoxy,
- R 1 and R 2 are both hydrogen, R 3 is amino and R 4 is hydrogen;
- R 1 and R 2 are independently selected from hydrogen, methyl, ethyl, propyl,
- R 1 is hydrogen or methyl and R 2 is selected from hydrogen, methyl, 2-hydroxyethyl, 2-aminoethyl, 4-aminobutyl, 3-(N-isopropylamino)propyl, 2-(dimethylamino)ethyl, 4-(dimethylamino)butyl, 2-pyrolidin- 1-ylethyl, 3-pyrolidin- 1-ylpropyl, 5-t-butyl-isoxazol-3-yl, 2-morpholin-4-ylethyl, 3-morpholin-4-ylpropyl, 2-piperidin-l-ylethyl, 3-piperidin-l-ylpropyl, 3-(4-methyl-piperazin-l-yl)propyl and 2,4-dimethoxybenzyl;
- R is hydrogen or methyl and R is selected from hydrogen, methyl, 2-hydroxyethyl, 2-methoxyethyl, 3-methoxypropyl, 2-(2-hydroxyethoxy)ethyl, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 2-(isopropylamino)ethyl, 3-(isopropylamino)propyl, 2-(dimethylamino)ethyl, 3-(dimethylamino)propyl, 4-(dimethylamino)butyl, 2-(dimethylamino)-l-methylethyl, carbamoylmethyl, 2-carbamoylethyl, 2-(2-methoxyethoxy)acetyl,
- R 1 is hydrogen and R 2 is selected from 2-morpholin-4-ylethyl, 3-morpholin-4-ylpropyl, 3-piperidin-l-ylpropyl, 2-piperidin-l-ylethyl, 2-pyrrolidin-l-ylethyl, 3-pyrrolidin-l-ylpropyl and 4-methyl-piperazin-l-yl;
- R 1 and R 2 are both hydrogen
- R 1 and R 2 are both (l-6C)alkyl (particularly (l-3C)alkyl);
- R 1 is hydrogen and R 2 is methyl;
- R 3 is selected from hydrogen, (l-3C)alkyl or (l-3C)alkoxy, wherein the (l-3C)alkyl and the (l-3C)alkoxy groups are optionally substituted by one or more groups (for example 1 or 2), which may be the same or different, selected from fluoro, hydroxy, (l-6C)alkyl, (l-6C)alkoxy, amino, mono(l-6C)alkylamino, di-[(l-6C)alkyl]amino, carbamoyl, mono(l-6C)alkylcarbamoyl or di-[(l-6C)alkyl]carbamoyl, a saturated or partially saturated 3 to 7 membered heterocyclic ring or a 5 or 6 membered heteroaryl ring, wherein said heterocyclic and heteroaryl rings are optionally independently substituted by one or more groups (for example 1 or 2), which may be the same
- R 3 is selected from hydrogen or (l-6C)alkyl, wherein the (l-6C)alkyl group is optionally substituted by one or more groups (for example 1 or 2), which may be the same or different, selected from fluoro, hydroxy, (l-6C)alkyl, (l-6C)alkoxy, amino, mono(l-6C)alkylamino, di-[(l-6C)alkyl]amino, carbamoyl, mono(l-6C)alkylcarbamoyl or di-[(l-6C)alkyl]carbamoyl, a saturated or partially saturated 3 to 7 membered heterocyclic ring or a 5 or 6 membered heteroaryl ring, wherein said heterocyclic and heteroaryl rings are optionally independently substituted by one or more groups (for example 1 or 2), which may be the same or different, selected from (l-4C)alkyl, (l-4C)alkoxy, hydroxy, amino,
- R 3 is selected from hydrogen and a group -NR ! R 2 as defined above (particularly -NH 2 );
- R 3 is a group -NR'R 2 as defined above (particularly -NH 2 );
- R 4 is independently selected from hydrogen and (l-6C)alkyl (particularly (l-3C)alkyl);
- R 3 is a group -NR'R 2 as defined above (particularly -NH 2 ) and R 4 is hydrogen;
- A is selected from phenyl, furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl and 1,3,5-triazinyl;
- A is selected from phenyl, oxazolyl, imidazolyl, pyrroiyl, pyrazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrazinyl and pyrimidyl.
- (nn) A is selected from phenyl, thiazolyl, thiadiazolyl, pyridyl and pyrimidinyl; (oo) A is phenyl;
- (oo') A is phenyl or pyridyl
- A is phenyl or pyridyl, wherein the nitrogen in the pyridyl ring is in the 3-position relateive to the alkyne bond.
- n 0, 1 or 2 (particularly 0 or 1, more particularly 0);
- (rr) n is 1 or 2 and R 5 is independently selected from halo, (l-6C)alkoxy and (l-6C)alkyl, wherein the (l-6C)alkyl and the (l-6C)alkoxy groups are optionally substituted by cyano or one or more fluoro;
- (rr) n is 1 or 2 and R 5 is independently selected from cyano, halo, (l-6C)alkoxy and (l-6C)alkyl, wherein the (l-6C)alkyl and the (l-6C)alkoxy groups are optionally substituted by cyano or one or more fluoro;
- n 0 or 1 and when n is 1, R 5 is (l-4C)alkyl (particularily methyl);
- (ss) n is 1 or 2 and R 5 is independently selected from cyclopropyl and (l-6C)alkyl, wherein the (l-6C)alkyl groups are optionally substituted by cyano or one or more fluoro; (tt) L is attached meta on ring A with respect to the point of attachment of the ethynyl group;
- (uu) L is attached meta on ring A with respect to the point of attachment of the ethynyl group and represents -N(R 8 )C(O)C(R a R b )-, -N(R 8 )C(O)N(R 9 )- or -N(R 8 )C(O)O-, wherein R 8 and R 9 independently represent hydrogen or (l- ⁇ C)alkyl and wherein R a and R b independently represent hydrogen or (l-6C)alkyl or R a and R b together with the carbon atom to which they are attached represent (3-6C)cycloalkyl;
- (vv) L is attached meta on ring A with respect to the point of attachment of the ethynyl group and represents -N(R 8 )C(O)C(R a R b )-, -N(R 8 )C(O)N(R 9 )- or -N(R 8 )C(O) O-, wherein R 8 and R 9 independently represent hydrogen or (l-3C)alkyl and wherein R a and R b independently represent hydrogen or (l-3C)alkyl;
- (vv') L is attached para on ring A with respect to the point of attachment of the ethynyl group;
- (ww) L is attached para on ring A with respect to the point of attachment of the ethynyl group and represents -N(R 8 )C(O) O- or -N(R 8 )C(O)N(R 9 )-, wherein R 8 and R 9 independently represent hydrogen or (l-6C)alkyl;
- A is selected from phenyl, furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl and 1,3,5-triazinyl (particularly phenyl, thiazolyl, thiadiazolyl, pyridyl and pyrimidinyl); n is 0; and L is attached meta on ring A with respect to the point of attachment of the ethynyl group and represents -N(R 8 )C(O)C(R a R b )-, -N(R 8 )C(O)N(R 9 )- or -N(R 8 )
- (yy) ' A is selected from phenyl, furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl and 1,3,5-triazinyl (particularly phenyl, thiazolyl, thiadiazolyl, pyridyl and pyrimidinyl); n is 0; and L is attached meta on ring A with respect to the point of attachment of the ethynyl group and represents -N(R 8 )C(O)C(R a R b )-, -N(R 8 )C(O)N(R 9 )- or -N(
- B is selected from oxetanyl, azetidinyl, thietanyl, pyrrolidinyl, , morpholinyl, 1,3-dioxolanyl, tetrahydrofuranyl, piperidyl, piperazinyl, thiomorpholinyl, tetrahydropyranyl, homopiperazinyl, pyrrolinyl, imidazolinyl, pyrazolinyl, pyranyl, tetrahydropyridinyl, 1,2,4- oxadiazolyl and dihydrothiopyranyl;
- B is an 8, 9 or 10 membered bicyclic group which optionally contains 1,2,3 or 4 heteroatoms independently selected from N, O and S and which is saturated, partially saturated or aromatic then B is selected from 2,3-dihydro-lH-indenyl, benzodioxinyl, 1,2,3,4-tetrahydronaphthalenyl, 1,2,3,4-tetrahydropentalene, benzofuranyl, 2,3-dihydrobenzofuranyl, benzimidazolyl, benzthienyl, benzthiazolyl, benzisothiazolyl, benzoxazolyl, benzisoxazolyl, pyridoimidazolyl, pyrimidoimidazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, phthalazinyl, cinnolinyl, indolyl, and naphthyridinyl. or B is selected from 2,3
- W is a 5-7 membered ring (including the bridging atoms), said W ring comprising carbon atoms or optionally further heteroatoms independently selected from oxygen, nitrogen and sulphur, wherein said bicyclic ring contains no more that 4 heteroatoms in total.
- Such rings include: pyrazolo[l,5-a]pyridinyl, pyrazolo[l,5-c]pyrimidinyl, pyrazolo[l ,5-a][l,3,5]triazinyl, 4,5-dihydropyrazolo[l,5-a]pyridinyl, 4H-pyrazolo[5,l- c][l,4]thiazinyl, 4H-pyrazolo[5,l-c][l,4]oxazinyl, 1,2-benzisoxazolyl, isoxazolo[5,4- bjpyridinyl, isoxazolo[5,4-d]pyrimidinyl, 4H-thiopyrano[3,4-d]isoxazolyl, 4H-pyrano[3,4- d]isoxazolyl, 7aH-indolyl, 7aH-pyrrolo[2,3-b]pyridin
- (zz' ") B is selected from a saturated or partially saturated 4 to 6 membered heterocyclic ring, an aryl group, a 5 or 6 membered heteroaryl ring selected from furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl, or a 8, 9 or 10 membered bicyclic group which optionally contains 1, 2, 3 or 4 heteroatoms independently selected from N, O and S and which is saturated, partially saturated or aromatic; (aaa) B is selected from a saturated or partially saturated 4 to 6 membered heterocyclic ring, an aryl group or a 5 or 6
- (aaa') B is selected from a saturated or partially saturated 4 to 6 membered heterocyclic ring, an aryl group or a 5 or 6 membered heteroaryl ring selected from furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl; (aaa' ') B is selected from a saturated or partially saturated 4 to 6 membered heterocyclic ring, or a 5 or 6 membered heteroaryl ring selected from furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazoly
- (ccc') B is selected from phenyl, 2,3-di-hydro-indenyl, piperidinyl, pyridyl, pyrazolyl, isothiazolyl, thiadiazolyl, isoxazolyl or benzodioxinyl;
- (ccc") B is selected from phenyl, piperidinyl, pyridyl, pyrazolyl, isothiazolyl, thiadiazolyl, isoxazolyl, benzodioxolyl or tetrahydropyranyl.
- (ccc') B is selected from phenyl, 2,3-di-hydro-indenyl, piperidinyl, pyridyl, pyrazolyl, isothiazolyl, thiadiazolyl, isoxazolyl, benzodioxinyl, benzodioxolyl or tetrahydropyranyl.
- (ddd) B is selected from piperidinyl, phenyl, isoxazolyl, isothiazolyl, thiadiazolyl, pyrazolyl and pyridyl;
- (eee) B is selected from phenyl, pyrazolyl, thiadiazolyl and isoxazolyl;
- (fff) B is phenyl
- B is a saturated or partially saturated 3 to 7 (particularly 4 to 6) membered heterocyclic ring that contains one or two heteroatoms (particularly one heteroatom) selected from oxygen and nitrogen;
- (jjj) B is a 8, 9 or 10 membered bicyclic group which optionally contains 1, 2 or 3
- A is phenyl; n is 0; and B is selected from a saturated or partially saturated 4 to 6 membered heterocyclic ring, an aryl group, a 5 or 6 membered heteroaryl ring selected from furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl or a 8, 9 or
- A is phenyl; n is 0; and B is selected from phenyl, pyrazolyl, thiadiazolyl and isoxazolyl;
- A is selected from phenyl, furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl and 1,3,5-triazinyl (particularly phenyl, thiazolyl, thiadiazolyl, pyridyl and pyrimidinyl); n is 0; L is attached meta on ring A with respect to the point of attachment of the ethynyl group and represents -N(R 8 )C(O)C(R a R b )-, -N(R 8 )C(O)N(R 9 )- or -N(R 8 )
- (qqq) R is selected from halo, cyano, a saturated or partially saturated 3 to 7 membered heterocyclic ring or an -N(R c )C(O)(l-6C)alkyl in which R c is hydrogen or (l-6C)alkyl; or R 6 is selected from (l-6C)alkyl or (l-6C)alkoxy, wherein the (l-6C)alkyl and the (l-6C)alkoxy groups are optionally substituted by one or more groups (for example 1 or 2), which may be the same or different, selected from cyano, fluoro, hydroxy and amino (particularly fluoro); (rrr) R 6 is selected from halo, cyano, a saturated or partially saturated 3 to 7 membered heterocyclic ring or -N(R c )C(O)(l-6C)alkyl in which R
- (ttt) R is selected from fluoro, chloro, acetylamino, methyl, propyl, tert-butyl. trifluoromethyl, cyclopropyl, cyclopropylmethyl, methoxy and morpholin-4-yl;
- R 6 is independently selected from halo, (l-6C)alky(optionally substituted by up to three groups independently selected from halo, particularily fluoro), (l-6C)alkoxy,
- R c is hydrogen or (l-6C)alkyl (particularily (l-4C)alkyl) or a saturated 3 to 7 membered heterocyclic ring (particularily morpholino).
- R 6 is independently selected from halo, trifluoromethyl, methyl, tert-butyl, methoxy, acetylamino or morpholino.
- R 6 is independently selected from halo, cyano, oxo, (3-7C)cycloalkyl, a saturated 3 to 7 membered heterocyclic ring (optionally substituted by (l-4C)alkyl),
- R c is hydrogen or (l-6C)alkyl (particularily (l-4C)alkyl), (l-6C)alkyl (optionally substituted by up to three groups independently selected from halo, particularily fluoro) or (l-6C)alkoxy.
- R 6 is independently selected from halo, trifluoromethyl, cyano, methyl, isopropyl, tert-butyl, methoxy, acetylamino, oxo, cyclopropyl or 4-methyl-piperazin-l-yl.
- R 6 is independently selected from (l-6C)alky or a (3-7C)cycloalkyl, particularily independently selected from (l-4C)alkyl or a (3-5C)cycloalkyl ring, more particularily independently selected from methyl, ethyl, propyl, isopropyl, sec -butyl, tert-butyl, cyclopropyl or cyclobutyl.
- (uuu) B is selected from cyclopentyl, cyclohexyl, piperidinyl, tetrahydropyranyl, phenyl, furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl,
- R 6 is independently selected from fluoro, chloro, cyano, acetylamino, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, trifluoromethyl, cyclopropyl, cyclopropylmethyl, methoxy, ethoxy, propoxy, butoxy and morpholin-4-yl;
- (vvv) B is selected from phenyl, isoxazolyl, isothiazolyl, thiadiazolyl, pyrazolyl and pyridyl; m is 1 or 2; and R is independently selected from halo, cyano, a (3-4C)cycloalkyl ring, a saturated or partially saturated 3 to 7 membered heterocyclic ring or -N(R c )C(O)(l-6C)alkyl in which R c is hydrogen or (l-6C)alkyl; or R 6 is selected from (l-6C)alkyl or (l-6C)alkoxy, wherein the (l-6C)alkyl and the (l-6C)alkoxy groups are optionally substituted by one or more groups (for example 1 or 2), which may be the same or different, selected from cyano, fluoro, hydroxy and amino (particularly fluoro);
- (www) B is selected from phenyl, isoxazolyl, isothiazolyl, thiadiazolyl, pyrazolyl and pyridyl; m is 1 or 2; and R is independently selected from fluoro, chloro, cyano, acetylamino, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, trifluoromethyl, cyclopropyl, cyclopropylmethyl, methoxy, ethoxy, propoxy, butoxy and morpholin-4-yl; (xxx) B is phenyl; m is 1 or 2; and R 6 is independently selected from fluoro, chloro, cyano, acetylamino, trifluoromethyl, cyclopropyl, cyclopropylmethyl, methoxy, ethoxy, propoxy, butoxy and morpholin-4-yl;
- (yyy) B is phenyl; m is 1 or 2; and R 6 is independently selected from fluoro and trifluoromethyl;
- (zzz) B is isoxazolyl; m is 1 or 2; and R 6 is independently selected from fluoro, chloro, cyano, acetylamino, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, trifluoromethyl, cyclopropyl, cyclopropylmethyl, methoxy, ethoxy, propoxy and butoxy;
- (aaaa) B is isoxazolyl; m is 1 or 2; and R 6 is independently selected from methyl, ethyl, propyl, isopropyl, butyl, tert-butyl (particularly methyl and tert-butyl, more particularly tert-butyl);
- (bbb) B is pyrazolyl; m is 1 or 2; and R 6 is independently selected from fluoro, chloro, cyano, acetylamino, methyl, ethyl,
- (bbbb')B is thiadiazolyl; m is 1 or 2; and R 6 is independently selected from methyl, ethyl, propyl, isopropyl, butyl, tert-butyl
- Ring B-R 6 wherein m is 0, 1 or 2 is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,5-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2-(trifluoromethyl)phenyl, 3-(trifluoromethyl)phenyl, 4-(trifluoromethyl)phenyl, 2-fluoro-5-(trifluoromethyl)phenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl
- (dddd) Ring B-R wherein m is 1 or 2 is selected from 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,5-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2-(trifluoromethyl)phenyl, 3-(trifluoromethyl)phenyl, 4-(trifluorornethyl)phenyl, 2-fluoro-5-(trifluoromethyl)phenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 2-acetamidophenyl, 3-acetamidophen
- R 1 and R 2 are independently selected from hydrogen, (l-6C)alkylsulfonyl, phenyl(CH 2 ) u - wherein u is 0, 1, 2, 3, 4, 5 or 6, (l-6C)alkanoyl, (l-6C)alkyl, (l-6C)alkoxycarbonyl, (3-6C)cycloalkyl(CH 2 ) x - in which x is O, 1, 2, 3, 4, 5 or 6 , or a 5 or 6 membered heteroaryl ring, or R and R together with the nitrogen atom to which they are attached represent a saturated or partially saturated 3 to 7 membered heterocyclic ring optionally containing another heteroatom selected from N or O; wherein the (l-6C)alkyl, the (l-6C)alkanoyl and the (3-6C)cycloalkyl groups are optionally substituted by one or more groups independently selected from fluoro, hydroxy, (l-6C)alkyl, (l-6C)alkoxy, (l
- R 3 is selected from hydrogen, (l-6C)alkyl or (l-6C)alkoxy, wherein the (l-6C)alkyl and the (l-6C)alkoxy groups are optionally substituted by one or more groups independently selected from fluoro, hydroxy, (l-6C)alkyl, (l-6C)alkoxy, amino, mono(l-6C)alkylamino, di-[(l-6C)alkyl]amino, carbamoyl, mono(l-6C)alkylcarbamoyl or di-[(l-6C)alkyl]carbamoyl, a saturated or partially saturated 3 to 7 membered heterocyclic ring or a 5 or 6 membered heteroaryl ring, wherein said heterocyclic and heteroaryl rings are optionally independently substituted by one or more of the following: (l-4C)alkyl, (l-4C)alkoxy, hydroxy, amino, mono(l-6C)alkylamino or di-[(l-6
- R 4 is selected from hydrogen, (l-6C)alkyl or (l-6C)alkoxy;
- R 5 is selected from cyclopropyl, cyano, halo, (l-6C)alkoxy or (l-6C)alkyl, wherein the
- (l-6C)alkyl and the (l-6C)alkoxy groups are optionally substituted by cyano or by one or more fluoro;
- n 0, 1, 2 or 3;
- L represents -C(R a R )C(O)N(R 9 )-, -N(R 8 )C(O)C(R a R b )-, -N(R 8 )C(O)N(R 9 )-, N(R 8 )C(O) O-, or -OC(O)-N(R 9 )-, wherein R 8 and R 9 independently represent hydrogen or (l-6C)alkyl and wherein R a and R b independently represent hydrogen or (l-6C)alkyl or R a and R b together with the carbon atom to which they are attached represent (3-6C)cycloalkyl ;
- B represents a (3-7C)cycloalkyl ring, a saturated or partially saturated 3 to 7 membered heterocyclic ring, an aryl group, a 5 or 6 membered heteroaryl ring selected from furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl, or a 8, 9 or 10 membered bicyclic group "which optionally contains 1, 2, 3 or 4 heteroatoms independently selected from N, O and S and which is saturated, partially saturated or aromatic;
- R 6 is selected from one of the following 2 groups:
- R 6 is selected from halo, cyano, oxo, a (3-7C)cycloalkyl ring, a saturated or partially saturated 3 to 7 membered heterocyclic ring and -N(R c )C(O)(l-6C)alkyl in which R c is hydrogen or (l-6C)alkyl; or R 6 is selected from (l-6C)alkyl, -S(O) p -(l-6C)alkyl wherein p is 0, 1 or 2, or (l-6C)alkoxy, wherein the (l-6C)alkyl, -S(O) p -(l-6C)alkyl and the (l-6C)alkoxy groups are optionally substituted by one or more groups independently selected from: cyano, fluoro, hydroxy, (l-6C)alkoxy, amino, mono(l-6C)alkylamino, di(l-6C)alkylamino, a (3-7C)cycloalkyl
- n O, 1, 2 or 3;
- B is a (3-7C)cycloalkyl ring or a saturated or partially saturated 3 to 7 membered heterocyclic ring or a saturated or partially saturated 8, 9 or 10 membered bicyclic group
- the rings and bicyclic group optionally bear 1 or 2 oxo or thioxo substituents; and salts thereof, particularily pharmaceutically acceptable salts thereof.
- R 1 and R 2 are independently selected from hydrogen, (l-6C)alkylsulfonyl, phenyl(CH 2 ) u - wherein u is 0, 1, 2, 3, 4, 5 or 6, (l-6C)alkanoyl, (l-6C)alkyl, (l-6C)alkoxycarbonyl,
- R 3 is selected from hydrogen, (l-6C)alkyl or (l-6C)alkoxy, wherein the (l-6C)alkyl and the (l-6C)alkoxy groups are optionally substituted by one or more groups independently selected from fluoro, hydroxy, (l-6C)alkyl, (l-6C)alkoxy, amino, mono(l-6C)alkylamino, di-[(l-6C)alkyl] amino, carbamoyl, mono(l-6C)alkylcarbamoyl or di-[(l-6C)alkyl]carbamoyl, a saturated or partially saturated 3 to 7 membered heterocyclic ring or a 5 or 6 membered heteroaryl ring, wherein said heterocyclic and heteroaryl rings are optionally independently substituted by one or more of the following: (l-4C)alkyl, (l-4C)alkoxy, hydroxy, amino, mono(l-6C)alkylamino or di-[(l-6C)
- A represents an aryl group or a 5 or 6 membered heteroaryl ring selected from furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl;
- R s is selected from cyclopropyl, cyano, halo, (l-6C)alkoxy or (l-6C)alkyl, wherein the (l-6C)alkyl and the (l-6C)alkoxy groups are optionally substituted by cyano or by one or more fluoro;
- n 0, 1 or 2;
- L is attached meta or para on ring A with respect to the point of attachment of the ethynyl group and represents -C(R a R b )C(O)N(R 9 )-, -N(R 8 )C(O)C(R a R b )-, -N(R 8 )C(O)N(R 9 )-, -N(R 8 )C(O) O-, or -OC(O)-N(R 9 )-, wherein R 8 and R 9 independently represent hydrogen or (l-6C)alkyl and wherein R a and R b independently represent hydrogenor (l-6C)alkyl or R a and R b together with the carbon atom to which they are attached represent (3-6C)cycloalkyl ;
- B represents a (3-7C)cycloalkyl ring, a saturated or partially saturated 3 to 7 membered heterocyclic ring, an aryl group, a 5 or 6 membered heteroaryl ring selected from furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl, or a 8, 9 or 10 membered bicyclic group which optionally contains 1, 2, 3 or 4 heteroatoms independently selected from N, O and S and which is saturated, partially saturated or aromatic;
- R 6 is selected from one of the following 2 groups: (i) R 6 is selected from halo, cyano, oxo, a (3-7C)cycloalkyl ring, a saturated or partially saturated 3 to 7 membered heterocyclic ring and -N(R c )C(O)(l-6C)alkyl in which R c is hydrogen or (l-6C)alkyl; or R 6 is selected from (l-6C)alkyl, -S(O) p -(l-6C)alkyl wherein p is 0, 1 or 2, or (l-6C)alkoxy, wherein the (l-6C)alkyl, -S(O) p -(l-6C)alkyl and the (l-6C)alkoxy groups are optionally substituted by one or more groups independently selected from: cyano, fluoro, hydroxy, (l-6C)alkoxy, amino, mono(l-6C)alkylamino, di(l-6C)alkylamin
- n 0, 1, 2 or 3;
- B is a (3-7C)cycloalkyl ring or a saturated or partially saturated 3 to 7 membered heterocyclic ring or a saturated or partially saturated 8, 9 or 10 membered bicyclic group
- the rings and bicyclic group optionally bear 1 or 2 oxo or thioxo substituents; and salts thereof, particularily pharmaceutically acceptable salts thereof.
- Another particular embodiment of the compounds of the Formula I is a compound of the Formula Id:
- R 1 and R 2 are independently selected from hydrogen, (l-6C)alkylsulfonyl, phenyl(CH 2 ) u - wherein u is 0, 1, 2, 3, 4, 5 or 6, (l-6C)alkanoyl, (l-6C)alkyl, (l-6C)alkoxycarbonyl, (3-6C)cycloalkyl(CH 2 ) x - in which x is 0, 1, 2, 3, 4, 5 or 6 , or a 5 or 6 membered heteroaryl ring, or R 1 and R 2 together with the nitrogen atom to which they are attached represent a saturated or partially saturated 3 to 7 membered heterocyclic ring optionally containing another heteroatom selected from N or O; wherein the (l-6C)alkyl, the (l-6C)alkanoyl and the (3-6C)cycloalkyl groups are optionally substituted by one or more groups independently selected from fluoro, hydroxy, (l-6C)alkyl, (l-6C)
- R 4 is selected from hydrogen, (l-6C)alkyl or (l-6C)alkoxy;
- A represents an aryl group or a 5 or 6 membered heteroaryl ring selected from furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl;
- R 5 is selected from cyclopropyl, cyano, halo, (l-6C)alkoxy or (l-6C)alkyl, wherein the (l-6C)alkyl and the (l-6C)alkoxy groups are optionally substituted by cyano or by one or more fluoro;
- n 0, 1, 2 or 3;
- L is attached meta or para on ring A with respect to the point of attachment of the ethynyl group and represents -C(R a R b )C(O)N(R 9 )-, -N(R 8 )C(O)C(R a R b )-, -N(R 8 )C(O)N(R 9 )-, -N(R 8 )C(O) O-, or -OC(O)-N(R 9 )-, wherein R 8 and R 9 independently represent hydrogen or (l-6C)alkyl and wherein R a and R independently represent hydrogen or (l-6C)alkyl or R a and R b together with the carbon atom to which they are attached represent (3-6C)cycloalkyl ;
- B represents a (3-7C)cycloalkyl ring, a saturated or partially saturated 3 to 7 membered heterocyclic ring, an aryl group, a 5 or 6 membered heteroaryl ring selected from furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or
- 1,3,5-triazinyl or a 8, 9 or 10 membered bicyclic group which optionally contains 1, 2, 3 or 4 heteroatoms independently selected from N, O and S and which is saturated, partially saturated or aromatic;
- R 6 is selected from one of the following 2 groups:
- R 6 is selected from halo, cyano, oxo, a (3-7C)cycloalkyl ring, a saturated or partially saturated 3 to 7 membered heterocyclic ring and -N(R c )C(O)(l-6C)alkyl in which R c is hydrogen or (l-6C)alkyl; or R 6 is selected from (l-6C)alkyl, -S(O) p -(l-6C)alkyl wherein p is 0, 1 or 2, or (l-6C)alkoxy, wherein the (l-6C)alkyl, -S(O) p -(l-6C)alkyl and the (l-6C)alkoxy groups are optionally substituted by one or more groups independently selected from: cyano, fluoro, hydroxy, (l-6C)alkoxy, amino, mono(l-6C)alkylamino, di(l-6C)alkylamino, a (3-7C)cycloalkyl
- R 6 is selected from halo, cyano, a (3-7C)cycloalkyl ring, a saturated or partially saturated 3 to 7 membered heterocyclic ring or -N(R c )C(O)(l-6C)alkyl in which R c is hydrogen or (l-6C)alkyl; or R 6 is selected from (l-6C)alkyl or (l-6C)alkoxy, wherein the (l-6C)alkyl and the (l-6C)alkoxy groups are optionally substituted by one or more groups independently selected from cyano, fluoro, hydroxy, (l-6C)alkoxy, amino, mono(l-6C)alkylamino, di-[(l-6C)alkyl]amino, a (3-7C)cycloalkyl ring or a saturated or partially saturated 3 to 7 membered heterocyclic ring;
- n 0, 1, 2 or 3;
- B is a (3-7C)cycloalkyl ring or a saturated or partially saturated 3 to 7 membered heterocyclic ring or a saturated or partially saturated 8, 9 or 10 membered bicyclic group, the rings and bicyclic group optionally bear 1 or 2 oxo or thioxo substituents;
- Another particular embodiment of the compounds of the Formula I is a compound of the Formula Ie:
- R 1 and R 2 are independently selected from hydrogen, (l-6C)alkylsulfonyl, phenyl(CH 2 ) u - wherein u is 0, 1, 2, 3, 4, 5 or 6, (l-6C)alkanoyl, (l-6C)alkyl, (l-6C)alkoxycarbonyl, (3-6C)cycloalkyl(CH 2 ) x - in which x is 0, 1, 2, 3, 4, 5 or 6 , or a 5 or 6 membered heteroaryl ring, or R 1 and R 2 together with the nitrogen atom to which they are attached represent a saturated or partially saturated 3 to 7 membered heterocyclic ring optionally containing another heteroatom selected from N or O; wherein the (l-6C)alkyl, the (l-6C)alkanoyl and the (3-6C)cycloalkyl groups are optionally substituted by one or more groups independently selected from fluoro, hydroxy, (l-6C)alkyl, (l-6C)alkoxy, (
- R 3 is selected from hydrogen, (l-6C)alkyl or (l-6C)alkoxy, wherein the (l-6C)alkyl and the (l-6C)alkoxy groups are optionally substituted by one or more groups independently selected from fluoro, hydroxy, (l-6C)alkyl, (l-6C)alkoxy, amino, mono(l-6C)alkylamino, di-[(l-6C)alkyl] amino, carbamoyl, mono(l-6C)alkylcarbamoyl or di-[(l-6C)alkyl]carbamoyl, a saturated or partially saturated 3 to 7 membered heterocyclic ring or a 5 or 6 membered heteroaryl ring, wherein said heterocyclic and heteroaryl rings are optionally independently substituted by one or more of the following: (l-4C)alkyl, (l-4C)alkoxy, hydroxy, amino, mono(l-6C)alkylamino or di-[(l-6C)
- R 4 is selected from hydrogen, (l-6C)alkyl or (l-6C)alkoxy;
- A represents an aryl group or a 5 or 6 membered heteroaryl ring selected from furyl, pyrroiyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl; • »
- L is attached meta or para on ring A with respect to the point of attachment of the ethynyl group and represents -C(R a R b )C(O)N(R 9 )-, -N(R 8 )C(O)C(R a R b )-, -N(R 8 )C(O)N(R 9 )-, -N(R 8 )C(O) O-, or -OC(O)-N(R 9 )-, wherein R 8 and R 9 independently represent hydrogen or (l-6C)alkyl and wherein R a and R b independently represent hydrogen or (l-6C)alkyl or R and R b together with the carbon atom to which they are attached represent (3-6C)cycloalkyl; B represents a (3-7C)cycloalkyl ring, a saturated or partially saturated 3 to 7 membered heterocyclic ring, an aryl group, a 5 or 6 membered heteroaryl ring selected from furyl
- R 6 is selected from one of the following 2 groups: (i) R 6 is selected from halo, cyano, oxo, a (3-7C)cycloalkyl ring, a saturated or partially saturated 3 to 7 membered heterocyclic ring and -N(R c )C(O)(l-6C)alkyl in which R c is hydrogen or (l-6C)alkyl; or R 6 is selected from (l-6C)alkyl, -S(O) p -(l-6C)alkyl wherein p is 0, 1 or 2, or (l-6C)alkoxy, wherein the (l-6C)alkyl, -S(O) p -(l-6C)alkyl and the (l-6C)alkoxy groups are optionally substituted by one or more groups independently selected from: cyano, fluoro, hydroxy, (l-6C)alkoxy, amino, mono(l-6C)alkylamino, di(l-6C)alkylamin
- n O, 1, 2 or 3; and when B is a (3-7C)cycloalkyl ring or a saturated or partially saturated 3 to 7 membered heterocyclic ring or a saturated or partially saturated 8, 9 or 10 membered bicyclic group, the rings and bicyclic group optionally bear 1 or 2 oxo or thioxo substituents; and salts thereof, particularily pharmaceutically acceptable salts thereof.
- Specific compounds of the present invention are one or more of the following:
- Further specific compounds of the present invention are one or more of the following:
- a compound of the Formula I, or a pharmaceutically acceptable salt thereof may be prepared by any process known to be applicable to the preparation of chemically-related compounds. Such processes, when used to prepare a compound of the Formula I are provided as a further feature of the invention and are illustrated by the following representative process variants. Necessary starting materials may be obtained by standard procedures of organic chemistry.
- R 1 , R 2 , R 3 , R 4 , R 5 , R 8 , n and A have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with an isocyanate of the formula IV:
- Ar is a suitable aryl group, for example phenyl, and R , m and B have any of the meanings defined hereinbefore except that any functional group is protected if necessary; or
- Lg 1 is a suitable displaceable group, for example halogeno (such as fluoro, chloro or bromo) and R 6 , m and B have any of the meanings defined hereinbefore except that any functional group is protected if necessary; or
- Lg 2 is a suitable displaceable group for example hydroxy, halogeno (such as fluoro, chloro or bromo), R x -C(O)-O- or R x -O- (wherein R x is a suitable alkyl or aryl group and R 6 , R a , R b , m and B have any of the meanings defined hereinbefore except that any functional group is protected if necessary; or Process (e) For compounds of the formula I wherein L is -N(R 8 )C(O)N(H)-, the reaction of a compound of the formula II as defined above with a trichloroacetylamine of the formula XHT.
- halogeno such as fluoro, chloro or bromo
- Lg 2 is a suitable displaceable group as described above and R 1 , R 2 , R 3 , R 4 , R 5 ,
- R a , R , n and A have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with an amine of the formula XV:
- Lg 4 is a suitable displaceable group for example halogeno (such as chloro, bromo or iodo) or a sulfonyloxy group (such as trifluoromethylsulfonyloxy) and R 5 , R 6 , n, m, A, B and L have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with an alkyne of the formula XVLTI:
- reaction of process (a) is conveniently carried out in the presence of a suitable inert solvent or diluent, for example a halogenated solvent such as dichloromethane, chloroform or carbon tetrachloride, an ether such as tetrahydrofuran or 1,4-dioxane, an amine such as pyridine or a dipolar aprotic solvent such as N,N-dimethylformamide or
- N,N-dimethylacetamide is conveniently carried out at a temperature in the range, for example, from ambient temperature to about 60°C, preferably at or near ambient temperature.
- a suitable base is, for example, an organic amine base such as pyridine or a trialkylamine (such as triethylamine or diisopropylethylamine).
- the reaction of process (b) is conveniently carried out in the presence of a suitable inert solvent or diluent, for example an ether such as tetrahydrofuran or 1,4-dioxane or a dipolar aprotic solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulfoxide.
- reaction is conveniently carried out at a temperature in the range, for example, from ambient temperature to about 120°C, preferably from about 80°C to about 100°C. Conveniently, this reaction may also be performed by heating the reactants in a sealed vessel using a suitable heating apparatus such as a microwave heater.
- Reaction Conditions for Process (c) The reaction of process (c) is conveniently carried out in the presence of a suitable base.
- a suitable base is, for example, an organic amine base such as pyridine or a trialkylamine (such as triethylamine or diisopropylethylamine) or, for example, an alkali or alkaline earth metal carbonate such as sodium carbonate or potassium carbonate.
- reaction of process (c) is conveniently carried out in the presence of a suitable inert solvent or diluent, for example a halogenated solvent such as dichloromethane, chloroform or carbon tetrachloride or an ether such as tetrahydrofuran or 1,4-dioxane.
- a suitable inert solvent or diluent for example a halogenated solvent such as dichloromethane, chloroform or carbon tetrachloride or an ether such as tetrahydrofuran or 1,4-dioxane.
- the reaction is conveniently carried out at a temperature in the range, for example, from about - 10°C to about 30°C, preferably at or near 0°C.
- a suitable coupling agent is, for example, a suitable peptide coupling agent, for example O-(7-azabenzotriazol-l-yl)-N,N,N',N'- tetramethyluronium hexafluorophosphate (HATU) or a suitable carbodiimide such as dicyclohexylcarbodiimide (DCC) or carbonyldiimidazole (CDI), optionally in the presence of a catalyst such as dimethylaminopyridine or hydroxybenzotriazole.
- HATU O-(7-azabenzotriazol-l-yl)-N,N,N',N'- tetramethyluronium hexafluorophosphate
- HATU O-(7-azabenzotriazol-l-yl)-N,N,N',N'- tetramethyluronium hexafluorophosphate
- HATU O-(7-azabenzotria
- a suitable base is, for example, an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, diisopropylethylamine, N-methylmorpholine or diazabicyclo[5.4.0]undec-7-ene.
- Another suitable base is, for example, an alkali or alkaline earth metal carbonate, for example sodium carbonate, potassium carbonate, caesium carbonate or calcium carbonate.
- reaction of process (d) is conveniently carried out in the presence of a suitable inert solvent or diluent, for example an ester such as ethyl acetate, a halogenated solvent such as dichloromethane, chloroform or carbon tetrachloride, an ether such as tetrahydrofuran or 1,4-dioxane, an aromatic solvent such as toluene or a dipolar aprotic solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyr olidin-2-one or dimethylsulfoxide.
- a suitable inert solvent or diluent for example an ester such as ethyl acetate, a halogenated solvent such as dichloromethane, chloroform or carbon tetrachloride, an ether such as tetrahydrofuran or 1,4-dioxane, an aromatic solvent such as toluene or a di
- reaction is conveniently carried out at a temperature in the range, for example, from about 0°C to about 120°C, preferably at or near ambient temperature.
- Reaction Conditions for Process (e) The reaction of process (e) is conveniently carried out in the presence of a suitable base.
- a suitable base is, for example, an organic amine base such as pyridine or a trialkylamine (such as triethylamine or diisopropylethylamine) or, for example, an alkali or alkaline earth metal carbonate, such as sodium carbonate, potassium carbonate, caesium carbonate or calcium carbonate.
- reaction of process (e) is conveniently carried out in the presence of a suitable inert solvent or diluent, for example an ether such as tetrahydrofuran or 1,4-dioxane or a dipolar aprotic solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulfoxide.
- a suitable inert solvent or diluent for example an ether such as tetrahydrofuran or 1,4-dioxane or a dipolar aprotic solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulfoxide.
- a suitable inert solvent or diluent for example an ether such as tetrahydrofuran or 1,4-dioxane or a dipolar aprotic solvent such as N,N-dimethyl
- Reaction Conditions for Process (f) The reaction of process (f) is conveniently carried out under the conditions as described above for process (d).
- Reaction Conditions for Process (g) The reaction of process (g) is conveniently carried out in the presence of a catalytic amount of a suitable acid.
- a suitable acid is, for example, hydrogen chloride,
- the reaction of process (g) may conveniently be carried out in the absence or the presence of a suitable inert solvent or diluent.
- a suitable inert solvent or diluent when used, is for example an alcohol such as ethanol, isopropanol or butanol or a dipolar aprotic solvent such as acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulfoxide.
- the reaction is conveniently carried out at a temperature in the range, for example, from ambient temperature to about 120°C, preferably from about 80°C to about 90°C.
- Reaction Conditions for Process (h) The reaction of process (h) is conveniently carried out in the presence of a suitable palladium catalyst, optionally in combination with a suitable copper catalyst.
- a suitable palladium catalyst is, for example, bis(triphenylphosphine)palladium dichloride, [1,1'- bis(diphenylphosphino)ferrocene] palladium dichloride or tetrakis(triphenylphosphine)palladium(0).
- a suitable copper catalyst is, for example, copper (I) iodide.
- the reaction of process .(h) is conveniently carried out in the presence of a suitable base.
- a suitable base is, for example, an organic amine base, such as a trialkylamine (for example triethylamine) or tetramethylguanidine.
- the reaction of process (h) may conveniently be carried out in the absence or presence of a suitable inert solvent or diluent, for example an ester such as ethyl acetate, an ether such as tetrahydrofuran or 1,4-dioxane or a dipolar aprotic solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulfoxide.
- a suitable inert solvent or diluent for example an ester such as ethyl acetate, an ether such as tetrahydrofuran or 1,4-dioxane or a dipolar aprotic solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulfoxide.
- a suitable inert solvent or diluent for example an ester such as ethyl
- Reaction Scheme 1 wherein Lg is a suitable displaceable group as described above and R 1 , R 2 , R 3 , R 4 , R 5 , R , n and A have any of the meanings defined hereinbefore except that any functional group is protected if necessary.
- the reaction of Reaction Scheme 1 is conveniently carried out under the conditions as described above for process (h).
- compounds of the formula II may be obtained by reaction of a pyrimidine of the formula VI with a protected alkyne of the formula Via and then with an amine of the formula Vlb as illustrated in Reaction Scheme 2:
- Lg 4 in the compounds of the formulae VI and Vlb are each a suitable displaceable group as described above
- Pg is a suitable protecting group, for example a trialkylsilyl group, such as trimethylsilyl or tert-butyldimethylsilyl or Me 2 (OH)C- and R 1 , R 2 ,
- Step (i) of Reaction Scheme 2 is the coupling of a protected alkyne of the formula Via to a pyrimidine of the formula VI. Step (i) is carried out under conditions as described above for process (h). Step (ii) of Reaction Scheme 2 is the deprotection of the alkyne under basic or acidic conditions to provide an unsubstituted alkyne. A person skilled in the art would readily be able to select the appropriate conditions for deprotection in step (ii).
- Step (iii) of Reaction Scheme 2 is the coupling of the alkyne to an amine of the formula Vlb.
- Step (iii) of Reaction Scheme 2 is carried out under conditions as described above for process (h).
- compounds of the formula II may be obtained by reaction of a compound of the formula Vic, wherein Lg 3 is a suitable displaceable group as described above and R 3 , R 4 , R 5 , R 8 , n and A have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with an amine of the formula HNR ⁇ R 2 using reaction conditions as described above for process (g).
- the starting materials of the formulae VI, VLT, Via, Vlb and Vic and the amine HMR R 2 are commercially available or they are known in the literature, or they can be prepared by standard processes known in the art.
- Isocyanates of the formula IV are commercially available or they are known in the literature, or they can be prepared by standard processes known in the art.
- the isocyanates can conveniently be prepared from the corresponding acids or acid chlorides via a Curtis reaction with for example azide or diphenylphosphoryl azide.
- the isocyanates can conveniently be prepared by reaction of the corresponding amine with phosgene or a phosgene equivalent, for example triphosgene, diphosgene or N,N' -carbonyldiimidazole (March I., Adv. Org. Chem., 4 th edition, 1992, page 1290, Wiley Interscience).
- Starting Materials for Process (b) Compounds of the formula II may be obtained by conventional procedures as discussed above.
- Aryl carbamates of the formula III are commercially available or they are known in the literature, or they can be prepared by standard processes known in the art.
- the aryl carbamates can be prepared by reaction of an amine of the formula V with an arylchloroformate as illustrated in Reaction Scheme 3:
- Reaction Scheme 3 wherein R 6 , m, B and Ar have any of the meanings defined hereinbefore except that any functional group is protected if necessary.
- the reaction of Reaction Scheme 3 is conveniently carried out in the presence of a suitable base.
- a suitable base is, for example, an organic amine base such as pyridine or a trialkylamine (such as triethylamine).
- the reaction is conveniently carried out in the presence of a suitable inert solvent or diluent, for example an ether such as tetrahydrofuran or 1,4-dioxane.
- the reaction is conveniently carried out at a temperature in the range, for example, from about -20°C to about 100°C, preferably at or near 0°C.
- the starting material of the formula V and the arylchloroformate are commercially available or they are known in the literature, or they can be prepared by standard processes known in the art.
- Starting Materials for Process (c) Compounds of the formula II may be obtained by conventional procedures as discussed above.
- Compounds of the formula XI are commercially available or they are known in the literature, or they can be prepared by standard processes known in the art.
- Starting Materials for Process (d) Compounds of the formula II may be obtained by conventional procedures as discussed above.
- Compounds of formula IX are commercially available or they are known in the literature, or they can be prepared by standard processes known in the art.
- Starting Materials for Process (e) Compounds of the formula LI may be obtained by conventional procedures as discussed above.
- Trichloroacetylamines of the formula XIII are commercially available or they are known in the literature, or they can be prepared by standard processes known in the art.
- Starting Materials for Process (f) Compounds of the formula XIV may be obtained by conventional procedures as discussed above.
- Amines of the formula XV are commercially available or they are known in the literature, or they can be prepared by standard processes known in the art.
- Starting Materials for Process (g) As the skilled person would appreciate, compounds of the formula XVI can be prepared using similar processes to those described above using the appropriate starting materials, for example, wherein the starting materials carry an, optionally protected, group Lg 3 in place of the -N ⁇ R 2 group.
- R 2 are commercially available or they are known in the literature, or they can be prepared by standard processes known in the art.
- Starting Materials for Process (h) Compounds of formula XVII are commercially available or they are known in the literature, or as the skilled person would appreciate they can be prepared using similar processes to those described above using the appropriate starting materials.
- compounds of the formula XVII wherein L is -N(R 8 )C(O)N(H)- may conveniently be obtained by reaction of an amine of the formula XVIIa with an aryl carbamate of the formula XVLIb as illustrated in Reaction Scheme 4: XVIIa XVI lb
- Alkynes of the formula XVIII are commercially available or as the skilled person would appreciate they can be prepared using similar processes to those described above using the appropriate starting materials.
- compounds of the formula XVIII may conveniently be obtained by reaction of a pyrimidine of the formula XVIIIa:
- the isocyanates can conveniently be prepared by reaction of the corresponding amine with phosgene or a phosgene equivalent, for example triphosgene, diphosgene or N,N' -carbonyldiimidazole (March J., Adv. Org. Chem., 4 th edition, 1992, page 1290, Wiley Interscience).
- Amines of the formula XV are commercially available or they are known in the literature, or they can be prepared by standard processes known in the art.
- Starting Materials for Process (i) Compounds of the formula XX are commercially available or they are known in the literature, or as the skilled person would appreciate they can be prepared using similar processes to those described above using the appropriate starting materials.
- Amines of formula XV are commercially available or they are known in the literature, or they can be prepared by standard processes known in the art.
- Compounds of the formula I can be converted into further compounds of the formula I using standard procedures conventional in the art.
- Examples of the types of conversion reactions that may be used include introduction of a substituent by means of an aromatic substitution reaction or of a nucleophilic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents.
- the reagents and reaction conditions for such procedures are well known in the chemical art.
- aromatic substitution reactions include the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group.
- nucleophilic substitution reactions include the introduction of an alkoxy group or of a monoalkylamino group, a dialkyamino group or a N-containing heterocycle using standard conditions.
- reduction reactions include the reduction of a carbon yl group to a hydroxy group with sodium borohydride or of a nitro group to an amino group by catalytic hydrogenation with a nickel catalyst or by treatment with iron in the presence of hydrochloric acid with heating.
- An example of a suitable conversion reaction is the conversion of a carbamate compound of the formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , n and A are as defined in claim 1, L is N(H)C(O)-O-, B is an optionally substituted phenyl group, to a compound of the formula I wherein L is N(H)C(O)NH and R 1 , R 2 , R 3 , R 4 , R 5 , n, B and A are as defined in claim 1.
- Such a conversion may be achieved using standard procedures, for example by reaction of the carbamate with an appropriate amine, for example under conditions as described above for process (b).
- Another example of a suitable conversion reaction is the conversion of a compound of the formula I wherein R 2 , R 3 , R 4 , R 5 , R 6 , n, m, A, B and L are as defined in claim 1 and R 1 and/or R 2 is hydrogen to a compound of the formula I wherein R 1 and/or R 2 is, for example, an optionally substituted (l-6C)alkoxycarbonyl group.
- R 1 and/or R 2 is, for example, an optionally substituted (l-6C)alkoxycarbonyl group.
- Such a conversion may be achieved using standard procedures, for example by substitution of one or both of the hydrogen atoms R 1 and or R 2 for a desired, optionally substituted, (l-6C)alkoxycarbonyl group.
- Certain compounds of Formula I are capable of existing in stereoisomeric forms.
- the invention encompasses all geometric and optical isomers of the compounds of formula I and mixtures thereof including racemates. Tautomers and mixtures thereof also form an aspect of the present invention.
- Isomers may be resolved or separated by conventional techniques, e.g. chromatography or fractional crystallisation.
- Enantiomers may be isolated by separation of a racemic or other mixture of the compounds using conventional techniques (e.g. chiral High Performance Liquid Chromatography (HPLC)).
- HPLC High Performance Liquid Chromatography
- the desired optical isomers may be made by reaction of the appropriate optically active starting materials under conditions which will not cause racemisation, or by derivatisation, for example with a homochiral acid followed by separation of the diastereomeric derivatives by conventional means (e.g.
- Protecting groups may be removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.
- Specific examples of protecting groups are given below for the sake of convenience, in which "lower", as in, for example, lower alkyl, signifies that the group to which it is applied preferably has 1-4 carbon atoms. It will be understood that these examples are not exhaustive. Where specific examples of methods for the removal of protecting groups are given below these are similarly not exhaustive. The use of protecting groups and methods of deprotection not specifically mentioned are, of course, within the scope of the invention.
- aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group.
- modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulfinyl or alkylsulfonyl.
- In vitro receptor tyrosine kinase inhibition assay To test for inhibition of Tie2 receptor tyrosine kinase, compounds are evaluated in a non-cell based protein kinase assay by their ability to inhibit the protein kinase enzyme phosphorylation of a tyrosine containing polypeptide substrate in an ELISA based microtitre plate assay. In this particular case, the assay was to determine the IC 50 , for three different recombinant human tyrosine kinases Tie2, KDR and Fit. To facilitate production of the tyrosine kinases, recombinant receptor genes were produced using standard molecular biology cloning and mutagenesis techniques.
- recombinant proteins fragments encoded within these genes consist of only the intracellular portion C-terminal portion of the respective receptor, within which is found the kinase domain.
- the recombinant genes encoding the kinase domain containing fragments were cloned and expressed in standard baculovirus/Sf21 system (or alternative equivalent).
- Lysates were prepared from the host insect cells following protein expression by treatment with ice-cold lysis buffer (20mM N-2-hydroxyethylpiperizine- N'-2-ethanesulphonic acid (HEPES) pH7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl 2 , 1 mM ethylene glycol-bis ( ⁇ -aminoethyl ether) N',N',N',N'- tetraacetic acid (EGTA), plus protease inhibitors and then cleared by centrifugation. Tie2, KDR and Fltl lysates were stored in aliquots at -80 °C.
- HEPES N-2-hydroxyethylpiperizine- N'-2-ethanesulphonic acid
- EGTA ethylene glycol-bis ( ⁇ -aminoethyl ether) N',N',N',N'- tetraacetic
- Constitutive kinase activity of these recombinant proteins was determined by their ability to phosphorylate a synthetic peptide (made up of a random co-polymer of Glutamic Acid, Alanine and Tyrosine in the ratio of 6:3:1). Specifically, Nunc MaxisorbTM 96-well immunoplates were coated with 100 microlitres of synthetic peptide Sigma P3899 (lmg/ml stock solution in PBS diluted 1:500 in PBS prior to plate coating) and incubated at 4 °C overnight. Plates were washed in 50 mM HEPES pH 7.4 at room temperature to remove any excess unbound synthetic peptide.
- KDR or Fltl activities were assessed by incubation of the appropriate freshly diluted lysates (1:200, 1:400 and 1:1000 respectively) in peptide coated plates for 60 minutes (Tie2) or 20 minutes for (KDR, Fit) at room temperature in 100 mM HEPES pH 7.4 , adenosine trisphosphate (ATP) at 5 micromolar (or Km concentration for the respective enzyme, 10 mM MnCl 2 , 0.1 mM Na 3 VO 4 , 0.2 mM DL-dithiothreitol (DTT), 0.1% Triton X-100 together with the test compound(s) in dissolved in DMSO (final concentration of 2.5%) with final compound concentrations ranging from 0.05 micromolar -100 micromolar.
- ATP adenosine trisphosphate
- Reactions were terminated by the removal of the liquid components of the assay followed by washing of the plates with PBS-T (phosphate buffered saline with 0.5% Tween 20) or an alternative equivalent wash buffer.
- PBS-T phosphate buffered saline with 0.5% Tween 20
- the immobilised phospho-peptide product of the reaction was detected by immunological methods. Firstly, plates were incubated for 4 hours at room temperature with murine monoclonal anti-phosphotyrosin -HRP (Horseradish Peroxidase) conjugated antibodies (4G10 from Upstate Biotechnology UBI 16-105).
- Cellular Tie2 autophosphorylation assay This assay is based on measuring the ability of compounds to inhibit autophosphorylation of the Tie2 receptor which normally leads to the production of "activated" receptor that in turn initiates the particular signal transduction pathways associated with the receptor function. Autophosphorylation can be achieved by a number of means. It is known that expression of recombinant kinase domains in baculoviral systems can lead to the production of phosphorylated and activated receptor. It is also reported that over expression of receptors in recombinant cell lines can itself lead to receptor autophosphorylation in the absence of the ligand (Heldin C-H. 1995 Cell : 80, 213-223; Blume-J. P, Hunter T.
- Natural Angl ligand can be isolated using standard purification technology from either tumour cell supernatants or alternatively the Angl gene can be cloned and expressed recombinantly using stand molecular biology techniques and expression systems. In this case one can either attempt to produce the ligand either in its native state or as recombinant protein which for example may have been genetically engineered to contain additional of purificationO tags (eg. polyhistidine peptides, antibody Fc domains) to facilitate the process.
- purificationO tags eg. polyhistidine peptides, antibody Fc domains
- EA.hy926/B3 or HUVEC cellular Tie2 receptor a Angl ligand stimulated cellular receptor phosphorylation assay can be constructed which can be used to analyse to determine the potential of compounds to inhibit this process.
- EA.hy926/B3 cells were grown in the appropriate tissue culture5 media plus 10% foetal calf serum (FCS) for two days in 6 well plates starting with an initial seeding density of 5xl0 5 cells/well. On the third day the cells were serum starved for a total of 2 hours by replacing the previous media with media containing only 1% FCS.
- FCS foetal calf serum
- the media was removed and replace with 1 ml of the test compound dilutions (compound dilutions made in serum starvation media yet keeping theO DMSO concentration below 0.8%).
- orthovanidate was added to a final concentration of 0.1 mM for the final 10 minutes of serum starvation.
- the ligand plus orthovandiate was added to stimulate autophosphorylation of the cellular Tie2 receptor (ligand can be added either as purified material diluted in serum starvation media or non-purified cell supernatant containing ligand e.g. when recombinantly expressed mammalian cells).
- the cells were cooled on ice washed with approximately 5mls with cold PBS containing 1 mM orthovanadate, after which 1 ml of ice cold lysis buffer ((20 mM Tris pH 7.6, 150 mM NaCl, 50 mM NaF, 0.1 % SDS, 1% NP40, 0.5 % DOC, 1 mM orthovanadate, 1 mM EDTA, 1 mM PMSF, 30 ⁇ l / ml Aprotinin, 10 ⁇ g/ml Pepstatin, 10 ⁇ g/ml Leupeptin) was addedthe cells and left on ice for 10- 20 minutes.
- ice cold lysis buffer ((20 mM Tris pH 7.6, 150 mM NaCl, 50 mM NaF, 0.1 % SDS, 1% NP40, 0.5 % DOC, 1 mM orthovanadate, 1 mM EDTA, 1 mM PMSF, 30 ⁇ l / ml
- the lysate was removed and transferred to a 1.5 ml Eppendorf tube and centrifuged for 3 minutes at 13000 rpm at 4 °C. 800 ⁇ l of each lysate was transferred to fresh 2 ml Eppendorf tubes for the immuno-precipitation.
- 3 mg 15 ⁇ l of anti-phospho-tyrosine antibody (Santa Cruz PY99 -sc-7020) was added to the lysates and left to incubate for 2 hours at 4 °C. 600 ⁇ l washed MagnaBind beads (goat anti-mouse IgG, Pierce 21354) were added to the lysates and the tubes left to rotate over night at 4 °C.
- All blots were treated with 5% Marvel in PBS-Tween forl hour at room temperature to reduce non-specific binding of the detection antibody.
- a rabbit anti-Tie2 (Santa Cruz sc-324) was added in a 1:500 dilution in 0.5 % Marvel / PBS- Tween and left to incubate overnight at 4 °C.
- the blots were rigorously washed with PBS- Tween before adding the goat anti rabbit -POD conjugate (Dako P0448) at a 1:5000 dilution in 0.5 % Marvel / PBS-Tween.
- the antibody was left on for 1 hour at room temperature before subsequently washing the blots with PBS-Tween.
- the western blots of the various immuno-precipitated samples were developed the blots with LumiGLO (NEB 7003). And transferred to an X-Ray cassette and films exposed for 15 sec / 30 sec and 60 sec. The relative strength of the protein band which pertains to the phosphorylated Tie2 receptor was evaluated using a FluorS BioRad image analyser system. The percentage phosphorylation for each test compound dilution series was determined from which IC 50 values were calculated by standard methods using the appropriate control samples as reference.
- Table A shows IC 50 data from Test (a) for the inhibition of Tie2 receptor tyrosine kinase in vitro and column 3 shows IC 50 data from Test (b) for the inhibition of autophosphorylation of Tie2 receptor tyrosine kinase.
- compositions of the invention which comprises a compound of the Formula I, or a pharmaceutically acceptable salt thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier.
- the compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal do
- compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art.
- compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.
- the amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration.
- a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 0.5 g of active agent (more suitably from 0.5 to 100 mg, for example from 1 to 30 mg) compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition.
- the size of the dose for therapeutic or prophylactic purposes of a compound of the Formula I will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well known principles of medicine.
- a compound of the Formula I for therapeutic or prophylactic purposes it will generally be administered so that a daily dose in the range, for example, 0.1 mg/kg to 75 mg/kg body weight is received, given if required in divided doses.
- a parenteral route is employed.
- a dose in the range for example, 0.1 mg/kg to 30 mg/kg body weight will generally be used.
- a dose in the range for example, 0.05 mg/kg to 25 mg/kg body weight will be used.
- Oral administration is however preferred, particularly in tablet form.
- unit dosage forms will contain about 0.5 mg to 0.5 g of a compound of this invention.
- the compounds according to the present invention as defined herein are of interest for, amongst other things, their antiangiogenic effect.
- the compounds of the invention are expected to be useful in the treatment or prophylaxis of a wide range of disease states associated with undesirable or pathological angiogenesis, including cancer, diabetes, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, lymphoedema, acute and chronic nephropathies, atheroma, arterial restenosis, autoimmune diseases, acute inflammation, excessive scar formation and adhesions, endometriosis, dysfunctional uterine bleeding and ocular diseases with retinal vessel proliferation.
- Cancer may affect any tissue and includes leukaemia, multiple myeloma and lymphoma.
- such compounds of the invention are expected to slow advantageously the growth of primary and recurrent solid tumours of, for example, the colon, breast, prostate, lungs and skin.
- the antiangiogenic properties of the compounds according to the present invention arise from their Tie2 receptor tyrosine kinase inhibitory properties.
- the compounds of the present invention are expected be useful to produce a Tie2 inhibitory effect in a warm-blooded animal in need of such treatment.
- the compounds of the present invention may be used to produce an antiangiogenic effect mediated alone or in part by the inhibition of Tie2 receptor tyrosine kinase. More particularly the compounds of the invention are expected to inhibit any form of cancer associated with Tie2.
- Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore, for use as a medicament for use as a medicament.
- a compound of the formula I, or a pharmaceutically acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use as a Tie2 receptor tyrosine kinase inhibitor in a warm-blooded animal such as man.
- a compound of the formula I, or a pharmaceutically acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use in the production of an anti-angiogenic effect in a warm-blooded animal such as man.
- a cancer selected from leukaemia, breast, lung, colon, rectal, stomach, prostate, bladder, pancreas, ovarian, lymphoma, testicular, neuroblastoma, hepatic, bile duct, renal cell, uterine, thyroid and skin cancer in a warm-blooded animal such as man.
- a method of inhibiting Tie2 receptor tyrosine kinase in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, as defined hereinbefore.
- a method for producing an anti-angiogenic effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, as defined hereinbefore.
- a method of treating cancers in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, as defined hereinbefore.
- a compound of the formula I, or a pharmaceutically acceptable salt thereof, as defined hereinbefore for use in the treatment of cancer.
- a cancer selected from leukaemia, breast, lung, colon, rectal, stomach, prostate, bladder, pancreas, ovarian, lymphoma, testicular, neuroblastoma, hepatic, bile duct, renal cell, uterine, thyroid or skin cancer.
- a compound of the present invention will possess activity against other diseases mediated by undesirable or pathological angiogenesis including psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, lymphoedema, acute and chronic nephropathies, atheroma, arterial restenosis, autoimmune diseases, acute inflammation, excessive scar formation and adhesions, endometriosis, dysfunctional uterine bleeding and ocular diseases with retinal vessel proliferation.
- the anti-angiogenic activity defined herein may be applied as a sole therapy or may involve, in addition to a compound of the invention, one or more other substances and/or treatments.
- Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment.
- the other component(s) of such conjoint treatment in addition to the cell cycle inhibitory treatment defined hereinbefore may be: surgery, radiotherapy or chemotherapy.
- Such chemotherapy may include one or more of the following categories of anti -tumour agents:
- anti-invasion agents for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function
- antiproliferative/antineoplastic drugs and combinations thereof as used in medical oncology, such as alkylating agents (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan and nitrosoureas); antimetabolites (for example antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside and hydroxyurea, or, for example, one of the preferred antimetabolites disclosed in European Patent Application No.
- 562734 such as (2S)-2- ⁇ o-fluoro-p-[N- ⁇ 2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)- N-(prop-2-ynyl)amino]benzamido ⁇ -4-(tetrazol-5-yl)butyric acid); antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like taxol and taxotere); and topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan and camptothecin
- inhibitors of growth factor function include growth factor antibodies, growth factor receptor antibodies, farnesyl transf erase inhibitors, tyrosine kinase inhibitors and serine/threonine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example the EGFR tyrosine kinase inhibitors N-(3-chloro-4- fluorophenyl)-7-methoxy-
- 6-(3-morpholinopropoxy)quinazolin-4-amine ZD 1839
- N-(3-ethynylphenyl)- 6,7-bis(2-methoxyethoxy)quinazolin-4-amine CP 358774
- 6-acrylamido-N-(3-chloro-4- fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine CI 1033
- antiangiogenic agents that work by different mechanisms to those defined hereinbefore, such as those which inhibit vascular endothelial growth factor such as the compounds disclosed in International Patent Applications WO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354 and those that work by other mechanisms (for example linomide, inhibitors of integrin ocv ⁇ 3 function and angiostatin);
- biotherapeutic therapeutic approaches for example those which use peptides or proteins (such as antibodies or soluble external receptor domain constructions) which either sequest receptor ligands, block ligand binding to receptor or decrease receptor signalling (e.g. due to enhanced receptor degradation or lowered expression levels)
- antisense therapies for example those which are directed to the targets listed above, such as ISIS 2503, an anti-ras antisense;
- gene therapy approaches including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; and
- immunotherapy approaches including for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies.
- cytokines such as interleukin 2, interleukin 4 or granulocyte-ma
- Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment.
- Such combination products employ the compounds of this invention within the dosage range described hereinbefore and the other pharmaceutically-active agent within its approved dosage range.
- a pharmaceutical product comprising a compound of the Formula I as defined hereinbefore and an additional anti-tumour substance as defined hereinbefore for the conjoint treatment of cancer.
- the compounds of Formula I and their pharmaceutically acceptable salts are also useful as pharmacological tools in the development and standardisation of in vitro and in vivo test systems for the evaluation of the effects of inhibitors of cell cycle activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
- the invention will now be illustrated by the following non limiting examples in which, unless stated otherwise:
- temperatures are given in degrees Celsius (°C); operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18-25 °C;
- organic solutions were dried over anhydrous magnesium sulfate; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 Pascals; 4.5-30 mmHg) with a bath temperature of up to 60 °C;
- chromatography means flash chromatography on silica gel; thin layer chromatography (TLC) was carried out on silica gel plates;
- NMR data is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300 MHz using perdeuterio dimethyl sulphoxide (DMSO-d 6 ) as solvent unless otherwise indicated; the following abbreviations have been used: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; b, broad;
- Example 7 was prepared by an analogous method to Example 1, using Intermediate 2 in place of Intermediate 1 and 2-fluoro-5-trifluoromethylphenyl isocyanate in place of phenyl isocyanate.
- Phenylchloroformate (0.84 mL) was added dropwise to a stirred solution of 5-[(4- aminophenyl)ethynyl]pyrimidine-4,6-diamine (Intermediate 2) (1.0 g) and pyridine (0.72 mL) in THF (75 mL) at 0°C. After 2 hr water (10 mL) was added, the reaction mixture stirred for 10 min then concentrated in vacuo.
- Phenyl (5-tert-butyl-l,3,4-thiadiazol-2-yl)carbamate Phenylchloroformate (0.6 mL) was added dropwise to 2-amino-5-tert-butyl-l,3,4-thiadiazole (0.5 g) and pyridine (0.51 mL) in THF (40 mL) at 0°C. After 2 hour, the reaction mixture was quenched with water (10 mL) and extracted with EtOAc (3x 10 mL). The combined organics were dried (MgSO 4 ), filtered and concentrated in vacuo. Purification by flash chromatography on silica using 20-50% EtOAc in isohexane gave the title compound as a yellow solid (0.819 mg, 93%)
- Examples 12 to 15 were prepared by an analogous method to Example 11 by reacting Intermediate 2 with the appropriate phenyl carbamate:
- Examples 16 to 18 were prepared by an analogous method to Example 11 but using Intermediate 1 in place of Intermediate 2 with the appropriate phenyl carbamate.
- Examples 19 and 20 were prepared by an analogous method to Example 16, except purification was carried out by trituration with ether.
- Example 19 N- ⁇ 3-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl ⁇ -N'-(3-methylisoxazol-5-yl)urea
- Example 23 N- ⁇ 3-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl ⁇ -N'-(2-morpholin-4-ylphenyl)urea
- Example 23 was prepared by an analogous method to Example 22 but using Intermediate 10 in place of Intermediate 9.
- Phenyl ⁇ 3-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl ⁇ carbamate (Example 10) (50 mg), 1- methylpiperidin-4-amine (34 mg) and triethylamine (44 mg) in THF (2 mL) were heated at reflux under an inert atmosphere for 18 hours. The solvent was evaporated and the residue was diluted with diethyl ether (10 mL). The product was filtered and dried in vacuo to afford the title compound as a beige solid (41 mg, 77%);
- Example 25 N- ⁇ 3-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyI ⁇ -N'-(l-propylpiperidin-4-yl)urea
- Example 25 was prepared by an analogous method to Example 24 by using 1-propylpiperidin-
- Phenylacetyl chloride (55.7 mg) and pyridine (47.5 mg) were added to a stirred solution of 5- [(3-aminophenyl)ethynyl]pyrimidine-4,6-diamine (intermediate 1)(67.6 mg) in THF. After 60 min, the reaction mixture was concentrated to give a yellow solid. Purification by flash chromatography on silica using 1-5% (7M ammonia in MeOH) in DCM as eluent to give the title compound as a yellow solid (23 mg, 23%);
- Examples 28 to 30 were prepared by an analogous method to Example 27 by using the appropriate acid in place of 2-methoxyphenylacetic acid.
- Example 31 N-(5-tert-butylisoxazol-3-yl)-N'- ⁇ 3-[(4-chloropyrimidin-5-yl)ethynyl]phe ⁇ yl ⁇ urea
- N-(5-tert-butylisoxazol-3-yl)-N- ⁇ 3-[(4-chloropyrimidin-5- yl)ethynyl]phenyl ⁇ urea (Intermediate 12) (195 mg), HC1 in ether (1.0M, 0.1 mL), liquid ammonia (3 mL) and THF (10 mL) was irradiated in a microwave (130°C, 6O0W) for 4 hours.
- Example 32 was prepared using an analogous method to Example 31 by using methylamine in place of ammonia.
- Example 31 The following Examples were made in a similar way to Example 31 by using the appropriate amine in place of ammonia.
- Phenyl chloroformate was added dropwise to a solution of 3-ethynylaniline (20.0 mL) and pyridine (24.1 mL) in THF (300 mL) at 0°C. The resultant solution was stirred at 0°C for 3.5 hours. Pyridine (7.5 mL) was added, followed by a-dditional phenyl chloroformate (6 mL) dropwise. Water (50 mL) was added and the THF removed in vacuo. The resultant aqueous suspension was extracted into ether, washed with llvl HC1, water and brine and concentrated in vacuo to give the title compound as a pale brown solid (27.5 g, 78%).
- Example 51 The following Example was made in a similar way to Example 21: Example 51
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/596,740 US20080027076A1 (en) | 2003-12-24 | 2004-12-20 | Pyrimidines With Tie2 (Tek) Activity |
EP04806134A EP1737462B1 (en) | 2003-12-24 | 2004-12-20 | Pyrimidines with tie2 (tek) activity |
DE602004015509T DE602004015509D1 (en) | 2003-12-24 | 2004-12-20 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY |
JP2006546305A JP2007517006A (en) | 2003-12-24 | 2004-12-20 | Pyrimidine with TIE2 (TEK) activity |
HK07106766A HK1102045A1 (en) | 2003-12-24 | 2007-06-25 | Pyrimidines with tie2 (tek) activity |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0330001A GB0330001D0 (en) | 2003-12-24 | 2003-12-24 | Compounds |
GB0330001.9 | 2003-12-24 | ||
GB0416850A GB0416850D0 (en) | 2004-07-29 | 2004-07-29 | Compounds |
GB0416850.6 | 2004-07-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005060969A1 true WO2005060969A1 (en) | 2005-07-07 |
Family
ID=34712716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2004/005332 WO2005060969A1 (en) | 2003-12-24 | 2004-12-20 | Pyrimidines with tie2 (tek) activity |
Country Status (11)
Country | Link |
---|---|
US (1) | US20080027076A1 (en) |
EP (1) | EP1737462B1 (en) |
JP (1) | JP2007517006A (en) |
AR (1) | AR046996A1 (en) |
AT (1) | ATE402705T1 (en) |
DE (1) | DE602004015509D1 (en) |
ES (1) | ES2309591T3 (en) |
HK (1) | HK1102045A1 (en) |
TW (1) | TW200524607A (en) |
UY (1) | UY28700A1 (en) |
WO (1) | WO2005060969A1 (en) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006044823A3 (en) * | 2004-10-18 | 2006-06-15 | Amgen Inc | Heteroaryl-substituted alkyne compounds and method of use |
WO2006082371A1 (en) * | 2005-02-01 | 2006-08-10 | Astrazeneca Ab | Pyrimidine compounds having tie2 (tek) inhibitory activity |
WO2006082373A1 (en) * | 2005-02-01 | 2006-08-10 | Astrazeneca Ab | Pyrimidine compounds having ties (tek) inhibitory activity |
WO2006082404A1 (en) * | 2005-02-05 | 2006-08-10 | Astrazeneca Ab | Compounds having tie2 (tek) inhibitory activity |
WO2007075869A3 (en) * | 2005-12-23 | 2007-11-29 | Ariad Pharma Inc | Bicyclic heteroaryl compounds |
JP2008534565A (en) * | 2005-03-31 | 2008-08-28 | アストラゼネカ アクチボラグ | Aminopyrimidine derivatives having Tie2 inhibitory activity |
WO2008155140A1 (en) * | 2007-06-20 | 2008-12-24 | Bayer Schering Pharma Aktiengesellschaft | Alkynylpyrimidines as tie2 kinase inhibitors |
WO2011092197A1 (en) * | 2010-01-26 | 2011-08-04 | Boehringer Ingelheim International Gmbh | 5-alkynyl pyrimidines and their use as kinase inhibitors |
US8278307B2 (en) | 2006-05-08 | 2012-10-02 | Ariad Pharmaceuticals, Inc. | Monocyclic Heteroaryl compounds |
US8461167B2 (en) | 2006-05-08 | 2013-06-11 | Ariad Pharmaceuticals, Inc. | Acetylenic heteroaryl compounds |
CN101389338B (en) * | 2005-12-23 | 2013-06-26 | 阿里亚德医药股份有限公司 | Bicyclic heteroaryl compounds |
EP2671891A2 (en) | 2008-06-27 | 2013-12-11 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
US8633183B2 (en) | 2010-01-26 | 2014-01-21 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyrimidines |
US8846664B2 (en) | 2008-11-12 | 2014-09-30 | Ariad Pharmaceuticals, Inc. | Pyrazinopyrazines and derivatives as kinase inhibitors |
US8916548B2 (en) | 2008-07-29 | 2014-12-23 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyrimidines |
AU2013201242B2 (en) * | 2005-12-23 | 2015-05-07 | Ariad Pharmaceuticals, Inc. | Bicyclic heteroaryl compounds |
WO2016008433A1 (en) * | 2014-07-17 | 2016-01-21 | Sunshine Lake Pharma Co., Ltd. | Substituted urea derivatives and pharmaceutical uses thereof |
AU2015210454B2 (en) * | 2005-12-23 | 2016-10-27 | Ariad Pharmaceuticals, Inc. | Bicyclic heteroaryl compounds |
US9493470B2 (en) | 2012-12-12 | 2016-11-15 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
WO2017222285A1 (en) * | 2016-06-20 | 2017-12-28 | 재단법인 대구경북첨단의료산업진흥재단 | Novel imidazopyridine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer |
WO2019011264A1 (en) * | 2017-07-13 | 2019-01-17 | Sunshine Lake Pharma Co., Ltd. | Salt of substituted urea derivative and use thereof in medicine |
WO2020013531A1 (en) * | 2018-07-10 | 2020-01-16 | 보로노이바이오 주식회사 | N-(3-(imidazo[1,2-b]pyridazine-3-ylethynyl)-4-methylphenyl)-5-phenyl-4,5-dihydro-1h-pyrazole-1-carboxamide derivative, and pharmaceutical composition containing same as active ingredient for treating kinase-related diseases |
WO2021172931A1 (en) * | 2020-02-28 | 2021-09-02 | 재단법인 대구경북첨단의료산업진흥재단 | 3-((8-((1h-pyrazol-4-yl)amino)imidazo[1,2-a]pyridin-3-yl)ethinyl)-n-phenylbenzamide derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT410913B (en) * | 2001-08-14 | 2003-08-25 | Schelling Anlagenbau Gmbh | SUPPORT TABLE FOR A CUTTING SAW WITH A MACHINE TABLE |
DE602004018193D1 (en) * | 2003-12-24 | 2009-01-15 | Astrazeneca Ab | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY |
EP2070929A1 (en) * | 2007-12-11 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
WO2020015615A1 (en) | 2018-07-17 | 2020-01-23 | 深圳市塔吉瑞生物医药有限公司 | Alkynyl (hetero) aromatic ring compounds used for inhibiting protein kinase activity |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002008205A1 (en) * | 2000-07-24 | 2002-01-31 | Krenitsky Pharmaceuticals, Inc. | Substituted 5-alkynyl pyrimidines having neurotrophic activity |
WO2003080064A1 (en) * | 2002-03-21 | 2003-10-02 | Abbott Laboratories | Kinase inhibitors |
WO2003080625A1 (en) * | 2002-03-21 | 2003-10-02 | Abbott Laboratories | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100521735B1 (en) * | 2000-02-25 | 2005-10-17 | 에프. 호프만-라 로슈 아게 | Adenosine receptor modulators |
-
2004
- 2004-12-20 DE DE602004015509T patent/DE602004015509D1/en not_active Expired - Fee Related
- 2004-12-20 AT AT04806134T patent/ATE402705T1/en not_active IP Right Cessation
- 2004-12-20 US US10/596,740 patent/US20080027076A1/en not_active Abandoned
- 2004-12-20 JP JP2006546305A patent/JP2007517006A/en active Pending
- 2004-12-20 WO PCT/GB2004/005332 patent/WO2005060969A1/en active IP Right Grant
- 2004-12-20 ES ES04806134T patent/ES2309591T3/en active Active
- 2004-12-20 EP EP04806134A patent/EP1737462B1/en not_active Not-in-force
- 2004-12-23 UY UY28700A patent/UY28700A1/en not_active Application Discontinuation
- 2004-12-24 TW TW093140595A patent/TW200524607A/en unknown
- 2004-12-27 AR ARP040104907A patent/AR046996A1/en unknown
-
2007
- 2007-06-25 HK HK07106766A patent/HK1102045A1/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002008205A1 (en) * | 2000-07-24 | 2002-01-31 | Krenitsky Pharmaceuticals, Inc. | Substituted 5-alkynyl pyrimidines having neurotrophic activity |
WO2003080064A1 (en) * | 2002-03-21 | 2003-10-02 | Abbott Laboratories | Kinase inhibitors |
WO2003080625A1 (en) * | 2002-03-21 | 2003-10-02 | Abbott Laboratories | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors |
Cited By (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006044823A3 (en) * | 2004-10-18 | 2006-06-15 | Amgen Inc | Heteroaryl-substituted alkyne compounds and method of use |
WO2006082371A1 (en) * | 2005-02-01 | 2006-08-10 | Astrazeneca Ab | Pyrimidine compounds having tie2 (tek) inhibitory activity |
WO2006082373A1 (en) * | 2005-02-01 | 2006-08-10 | Astrazeneca Ab | Pyrimidine compounds having ties (tek) inhibitory activity |
JP2008528663A (en) * | 2005-02-01 | 2008-07-31 | アストラゼネカ アクチボラグ | Pyrimidine compounds having Ties (TEK) inhibitory activity |
WO2006082404A1 (en) * | 2005-02-05 | 2006-08-10 | Astrazeneca Ab | Compounds having tie2 (tek) inhibitory activity |
JP2008534565A (en) * | 2005-03-31 | 2008-08-28 | アストラゼネカ アクチボラグ | Aminopyrimidine derivatives having Tie2 inhibitory activity |
US8114874B2 (en) | 2005-12-23 | 2012-02-14 | Ariad Pharmaceuticals, Inc. | Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors |
JP2013064004A (en) * | 2005-12-23 | 2013-04-11 | Ariad Pharmaceuticals Inc | Bicyclic heteroaryl compound |
EP3747441A1 (en) * | 2005-12-23 | 2020-12-09 | ARIAD Pharmaceuticals, Inc. | Bicyclic heteroaryl compounds |
EA034598B1 (en) * | 2005-12-23 | 2020-02-25 | Ариад Фармасьютикалз, Инк. | Use of bicyclic heteroaryl compounds for treating cancer |
JP2009521462A (en) * | 2005-12-23 | 2009-06-04 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Bicyclic heteroaryl compounds |
EP1973545A4 (en) * | 2005-12-23 | 2010-03-10 | Ariad Pharma Inc | Bicyclic heteroaryl compounds |
EP3417912A1 (en) * | 2005-12-23 | 2018-12-26 | ARIAD Pharmaceuticals, Inc. | Bicyclic heteroaryl compounds |
EA027573B1 (en) * | 2005-12-23 | 2017-08-31 | Ариад Фармасьютикалз, Инк. | Bicyclic heteroaryl compounds |
AU2013201242B2 (en) * | 2005-12-23 | 2015-05-07 | Ariad Pharmaceuticals, Inc. | Bicyclic heteroaryl compounds |
WO2007075869A3 (en) * | 2005-12-23 | 2007-11-29 | Ariad Pharma Inc | Bicyclic heteroaryl compounds |
EP2495016A1 (en) * | 2005-12-23 | 2012-09-05 | Ariad Pharmaceuticals, Inc. | Bicyclic Heteroaryl Compounds |
US9029533B2 (en) | 2005-12-23 | 2015-05-12 | Ariad Pharmaceuticals, Inc. | Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors |
AU2006331673B2 (en) * | 2005-12-23 | 2013-02-28 | Ariad Pharmaceuticals, Inc. | Bicyclic heteroaryl compounds |
EP1973545A2 (en) * | 2005-12-23 | 2008-10-01 | Ariad Pharmaceuticals, Inc. | Bicyclic heteroaryl compounds |
KR101436303B1 (en) | 2005-12-23 | 2014-09-02 | 어리어드 파마슈티칼스, 인코포레이티드 | Bicyclic heteroaryl compounds |
US8470851B2 (en) | 2005-12-23 | 2013-06-25 | Ariad Pharmaceuticals, Inc. | Substituted acetylenic imidazo[1,2-A]pyridine compounds as kinase inhibitors |
CN101389338B (en) * | 2005-12-23 | 2013-06-26 | 阿里亚德医药股份有限公司 | Bicyclic heteroaryl compounds |
AU2015210454B2 (en) * | 2005-12-23 | 2016-10-27 | Ariad Pharmaceuticals, Inc. | Bicyclic heteroaryl compounds |
CN103044432B (en) * | 2005-12-23 | 2016-08-03 | 阿里亚德医药股份有限公司 | Bicyclic heteroaryl compounds |
US9278971B2 (en) | 2005-12-23 | 2016-03-08 | Ariad Pharmaceuticals, Inc. | Substituted acetylenic pyrazolo[1,5-a]pyrimidines as kinase inhibitors |
JP2015147796A (en) * | 2005-12-23 | 2015-08-20 | アリアド・ファーマシューティカルズ・インコーポレイテッド | bicyclic heteroaryl compounds |
US8778942B2 (en) | 2005-12-23 | 2014-07-15 | Ariad Pharmaceuticals, Inc. | Substituted acetylenic imidazo[1,2-A]pyrazine compounds as kinase inhibitors |
US8461167B2 (en) | 2006-05-08 | 2013-06-11 | Ariad Pharmaceuticals, Inc. | Acetylenic heteroaryl compounds |
US9090561B2 (en) | 2006-05-08 | 2015-07-28 | Ariad Pharmaceuticals, Inc. | Acetylenic heteroaryl compounds |
US8278307B2 (en) | 2006-05-08 | 2012-10-02 | Ariad Pharmaceuticals, Inc. | Monocyclic Heteroaryl compounds |
CN101679310B (en) * | 2007-06-20 | 2012-08-08 | 拜耳先灵医药股份有限公司 | Alkynylpyrimidines as Tie2 kinase inhibitors |
JP2010530396A (en) * | 2007-06-20 | 2010-09-09 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | Alkynyl pyrimidines as TIE2 kinase inhibitors |
US8642611B2 (en) | 2007-06-20 | 2014-02-04 | Bayer Intellectual Property Gmbh | Alkynylpyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
WO2008155140A1 (en) * | 2007-06-20 | 2008-12-24 | Bayer Schering Pharma Aktiengesellschaft | Alkynylpyrimidines as tie2 kinase inhibitors |
EP2022785A1 (en) * | 2007-06-20 | 2009-02-11 | Bayer Schering Pharma Aktiengesellschaft | Alkynylpyrimidines as Tie2 kinase inhibitors |
EP2671891A2 (en) | 2008-06-27 | 2013-12-11 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
US8916548B2 (en) | 2008-07-29 | 2014-12-23 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyrimidines |
US8846664B2 (en) | 2008-11-12 | 2014-09-30 | Ariad Pharmaceuticals, Inc. | Pyrazinopyrazines and derivatives as kinase inhibitors |
US8633183B2 (en) | 2010-01-26 | 2014-01-21 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyrimidines |
US9321771B2 (en) | 2010-01-26 | 2016-04-26 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyrimidines |
US8618111B2 (en) | 2010-01-26 | 2013-12-31 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyrimidines |
WO2011092197A1 (en) * | 2010-01-26 | 2011-08-04 | Boehringer Ingelheim International Gmbh | 5-alkynyl pyrimidines and their use as kinase inhibitors |
US10662197B2 (en) | 2012-12-12 | 2020-05-26 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 3-(imidazo[1,2-b)pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
US11192895B2 (en) | 2012-12-12 | 2021-12-07 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
US10125136B2 (en) | 2012-12-12 | 2018-11-13 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
US11384086B2 (en) | 2012-12-12 | 2022-07-12 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
US9493470B2 (en) | 2012-12-12 | 2016-11-15 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
US11279705B2 (en) | 2012-12-12 | 2022-03-22 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
US11192896B2 (en) | 2012-12-12 | 2021-12-07 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
US11192897B2 (en) | 2012-12-12 | 2021-12-07 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
EP3169671A4 (en) * | 2014-07-17 | 2018-02-28 | Sunshine Lake Pharma Co., Ltd. | Substituted urea derivatives and pharmaceutical uses thereof |
WO2016008433A1 (en) * | 2014-07-17 | 2016-01-21 | Sunshine Lake Pharma Co., Ltd. | Substituted urea derivatives and pharmaceutical uses thereof |
WO2017222287A1 (en) * | 2016-06-20 | 2017-12-28 | 재단법인 대구경북첨단의료산업진흥재단 | Novel imidazopyridine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer |
WO2017222285A1 (en) * | 2016-06-20 | 2017-12-28 | 재단법인 대구경북첨단의료산업진흥재단 | Novel imidazopyridine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer |
US10870647B2 (en) | 2016-06-20 | 2020-12-22 | Daegu-Gyeongbuk Medical Innovation Foundation | Imidazopyridine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer |
WO2019011264A1 (en) * | 2017-07-13 | 2019-01-17 | Sunshine Lake Pharma Co., Ltd. | Salt of substituted urea derivative and use thereof in medicine |
WO2020013531A1 (en) * | 2018-07-10 | 2020-01-16 | 보로노이바이오 주식회사 | N-(3-(imidazo[1,2-b]pyridazine-3-ylethynyl)-4-methylphenyl)-5-phenyl-4,5-dihydro-1h-pyrazole-1-carboxamide derivative, and pharmaceutical composition containing same as active ingredient for treating kinase-related diseases |
WO2021172931A1 (en) * | 2020-02-28 | 2021-09-02 | 재단법인 대구경북첨단의료산업진흥재단 | 3-((8-((1h-pyrazol-4-yl)amino)imidazo[1,2-a]pyridin-3-yl)ethinyl)-n-phenylbenzamide derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer |
Also Published As
Publication number | Publication date |
---|---|
ES2309591T3 (en) | 2008-12-16 |
HK1102045A1 (en) | 2007-11-02 |
EP1737462B1 (en) | 2008-07-30 |
US20080027076A1 (en) | 2008-01-31 |
ATE402705T1 (en) | 2008-08-15 |
EP1737462A1 (en) | 2007-01-03 |
JP2007517006A (en) | 2007-06-28 |
TW200524607A (en) | 2005-08-01 |
DE602004015509D1 (en) | 2008-09-11 |
UY28700A1 (en) | 2005-07-29 |
AR046996A1 (en) | 2006-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1737462B1 (en) | Pyrimidines with tie2 (tek) activity | |
US20080153838A1 (en) | Compounds Having Tie2 (Tek) Activity | |
US20080194552A1 (en) | Aminopyrimidine Derivatives With Tie2 Inhibiting Activity | |
US20080146599A1 (en) | Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity | |
EP1737463B1 (en) | Pyrimidines with tie2 (tek) activity | |
US20100048543A1 (en) | Pyrimidine compounds having ties (tek) inhibitory activity | |
MX2009002046A (en) | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders. | |
MX2011006754A (en) | Pyrimidine indole derivatives for treating cancer. | |
CA2494421A1 (en) | Condensed pyridines and pyrimidines with tie2 (tek) activity | |
ZA200504827B (en) | Therapeutic agents | |
US7476677B2 (en) | Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of Tie2 | |
ES2393215T3 (en) | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10596740 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006546305 Country of ref document: JP Ref document number: 2004806134 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 847/MUMNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200480041936.3 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2004806134 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10596740 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2004806134 Country of ref document: EP |